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Summary
Prostate cancer is the second most prevalent non-cutaneous malignancy affecting men in the world. 
The current method for screening and diagnosis of prostate cancer relies on the measurement of serum 
kallikrein 3 (KLK-3) in conjunction with the digital rectal exam. However, serum KLK-3 or prostate 
specific antigen (PSA) as it is better known, is also elevated by benign prostate hyperplasia (BPH). 
Consequently, a major challenge in the diagnosis of prostate cancer is the ability to discriminate 
between prostate cancer and BPH. Misdiagnosis of prostate cancer entails unnecessary treatment for 
patients which results in psychological stress and physical discomfort. Despite the ineffectiveness of 
PSA as a biomarker, it is still the primary diagnostic tool. This is largely due to lack of an alternative and 
it is therefore crucial to find a new biomarker which can distinguish malignant prostate cancer from BPH. 
In this study, the secretome and proteome of four prostate cell lines (BPH-1, LNCaP, PC3 and PNT2) 
were investigated to identify novel biomarkers for BPH using a MS based proteomic approach. The 
analysis of the secretome necessitated that the growth conditions of prostate cell lines were optimized 
to reduce cell death and maximize secreted proteins. Optimal seeding densities were selected following 
measurements of total protein, LDH and the LDH/protein ratio. Subsequent optimization of protein 
precipitation methods identified acetone precipitation as the most suitable method for isolating protein 
from the conditioned media of prostate cell lines. The cell proteome of the four prostate cell lines was 
comparatively analysed by LC-MS/MS. The total number of proteins identified per cell line were as 
follows: 2079 in BPH-1, 2081 in LNCaP, 1853 in PC3 and 2137 proteins in the PNT2 cell line. A literature 
search of the proteins unique to BPH-1 identified mesencephalic astrocyte-derived neurotrophic factor 
(MANF) as a potential biomarker for BPH. Ingenuity pathway analysis was subsequently used to 
analyse and identify aberrant pathways in BPH-1. The following pathways were significantly altered in 
BPH-1: antiproliferative role of transducer of ERB2 in T cell signalling, pyrimidine ribonucleotide de novo 
biosynthesis, cell signalling and vitamin and mineral metabolism. The optimised secretome samples 
could not be analysed due to technical difficulties beyond our control. As a proof of concept preliminary 
analysis of the cell secretome from PC3 and BPH-1 cell lines yielded forty-six and ninety-nine proteins 
which were unique to each cell line, respectively. The identification of MANF and the antiproliferative 
role of transducer of ERB2 in T cell signalling during the proteomic analysis both pointed towards an 
inflammatory response in BPH. Differences in inflammation could therefore be explored in future in 
order to develop biomarkers unique to BPH and prostate cancer.   
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Opsomming 
Prostaatkanker is die tweede mees algemene kanker ter wêreld wat in mans voorkom. Die huidige 
metode vir die diagnosering van prostaatkanker is afhanklik van serum kallikrein-3(KLK-3)vlakke 
tesame met ‘n digitale rektumondersoek. Serumvlakke van KLK-3, beter bekend as prostaat-spesifieke-
antigeen (PSA), is egter ook verhoog tydens nie-kwaadaardige prostaathiperplasie (BPH). Gevolglik is 
'n groot uitdaging in die diagnose van prostaatkanker die vermoë om te onderskei tussen 
prostaatkanker en BPH. Die misdiagnose van prostaatkanker lei tot onnodige behandelings vir pasiënte 
wat sielkundige stres en fisiese ongemak tot gevolg kan hê. Ten spyte van die feit dat PSA oneffektief 
is as ‘n biomerker word dit steeds gebruik as ‘n primêre of hoof diagnostiese hulpmiddel. Die rede 
hiervoor kan grootliks toegeskryf word aan ‘n tekort aan alternatiewe hulpmiddels en dus om hierdie 
rede is dit noodsaaklik om ‘n nuwe biomerker te identifiseer wat kan onderskei tussen prostaatkanker 
en BPH.  
In hierdie studie is die sekretoom en proteoom van vier sellyne (BPH-1, LNCaP, PC3 en PNT2) 
ondersoek om nuwe biomerkers te identifiseer vir BPH deur gebruik te maak van ‘n MS gebasseerde 
proteomiese benadering. Die analiese van die sekretoom het vereis dat die groeikondisies van die 
prostaatkanker-sellyne geoptimiseer word om seldood te vermy, maar terselfde tyd die maksimum 
afskeiding van proteiene tot gevolg het. Optimale groeidigthede was geselekteer gevolg deur die 
bepaling van die totale proteïen, LDH en die LDH/proteïen-verhouding. Die optimisering van 
proteïenpresipitasie-metodes het asetoonpresipitasie identifiseer as die mees geskikte metode vir die 
isolering van proteïene  vanuit prostaatsellyne se gekondisioneerde groeimedium. Die selproteoom van 
die vier prostaat-sellyne is in ‘n relatiewe manier geanaliseer deur gebruik te maak van LC-MS/MS. Die 
totale aantal proteïene wat geidentifiseer is per sellyn was as volg: 2079 in BPH-1, 2081 in LNCaP, 
1853 in PC3 en 2137 proteïene in die PNT2 sellyn. ‘n Literatuurstudie van proteïene uniek aan BPH-1 
het die mesencefaliese-astrosiet-afgeleide neurotrofe-faktor (MANF) as ‘n potensiële biomerker vir BPH 
identifiseer. “Ingenuity pathway analysis”-sagteware is gevolglik gebruik om padweë wat afwyk te 
analiseer en identifiseer. Die volgende padweë is aansienlik verander in BPH-1: die antiprolifererende 
rol van die “transducer” ERB2 in T-sel seinoordrag, pirimidienribonukleotied de novo biosintese sowel 
as selsein-, vitamien- en mineral-metabolisme. Die optimiseerde sekretoommonsters kon weens 
onvoorsiene tegniese probleme nie geanaliseer word nie. Ten spyte hiervan dien die voorlopige 
analieses van die selsekretoon van PC3 and BPH-1 sellyne as konsepondersteuning en het 
onderskeidelik ses-en-veertig en nege-en-negentig proteïene opgelewer wat uniek is aan elke sellyn. 
Die identifikasie van MANF en die antiprolifererende rol van die “transducer” ERB2 in T-sel seinoordrag 
gedurende die proteomiese analieses is beide ‘n aanduiding van inflammatoriese reaksies in BPH. In 
toekomstigie studies kan die verskille in inflammasie dus gebruik word om biomerkers uniek aan BPH 
en prostaatkanker te ondersoek. 
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Chapter 1  
An introduction to prostatic diseases and 




1.1 Anatomy of the prostate 
The prostate is an ovoid shaped gland located below the bladder, anterior to the rectum and surrounding 
the urethra (figure 1.1) (1). It is composed of tubuloalveolar glands encapsulated by a layer of 
connective tissue made up of collagen and a layer composed of abundant smooth muscle which makes 
up the prostatic stroma (1). The connective tissue and fibrous smooth muscle provide support for 
glandular epithelial and stromal cells. A double layer of epithelial cells lines the ducts that branch out 
from the urethra before terminating into acini (3,4). Luminar epithelial cells are cuboidal in shape and 











Figure 1.1:  Location of the prostate relative to the genitourinary system (Modified from http:// 
intimatehealthhelp.net). 
The prostate is divided into four regions, namely the anterior fibromuscular stroma, central zone, 
transition zone and peripheral zone (figure 1.2). The peripheral zone contributes 70% of the glandular 
prostate  and spans the lateral and dorsal section (4). Most prostate cancers originate in the peripheral 
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zone contributes 5-10% of the glandular prostate and is located lateral and anterior to the urethra (5,6). 
It is separated from the peripheral zone by dense fibromuscular stroma. The transition zone is the site 
from which benign prostatic hyperplasia (BPH) develops and progresses (1). The central zone 
represents 25% of the glandular prostate and surrounds the ejaculatory ducts (5). The anterior 
fibromuscular stroma is the non-glandular part of the prostate comprising of dense fibromuscular tissue 
(5,6). It represents approximately one third of the prostate extending from the anterior of the urethra 
before fusing with the bladder muscle and neck of the external sphincter (2,5)  
The major function of the prostate gland is the production of seminal fluid which nourishes, protects and 
aids in the mobility of sperm (1). During ejaculation the prostate dispenses a slightly acidic fluid which 
contributes approximately 30% of the total ejaculate volume (4). Prostatic fluid contains hormones, ions, 












Figure 1.2:  Zonal anatomy of the prostate (Modified from http://www.aboutcancer.com). 
seminal fluid is derived from seminal vesicles, testicles and bulbourethral glands (1). The prostatic 
fraction of the ejaculate is also characterized by the presence of two enzymes, namely prostatic acid 
phosphatase (PAP) and kallikrein-3 (KLK3), which is more commonly known as prostate specific 
antigen (PSA). PAP is a tyrosine phosphatase implicated in the regulation of PCa cell proliferation (6). 
PSA is a serine protease which cleaves seminogelin in the seminal coagulum. This serves to liquefy 
the seminal coagulum and hence increase motility of sperm (2). Disturbed prostate function caused by 
malignant or benign tumours results in disruption of the basal cell layer and basement membrane 
causing leakage of PSA into general circulation. PSA can therefore be utilized as a serological marker 




Anterior firbromuscular stroma 
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Androgens, which are steroid hormones, and growth factors are essential for the optimal functioning, 
growth and differentiation of the prostate (7). Testosterone is the principal circulatory androgen and is 
produced by the Leydig cells of the testes. In the prostate testosterone is converted to 5α-
dihydrotestosterone (DHT) by the enzyme steroid 5α-reductase (SRD5A) (1). DHT is the most potent 
natural androgen and readily binds to an intracellular androgen receptor (AR) which is present in 
prostate epithelial and stromal cells (2,9). Activated AR’s form homodimers which translocate into the 
nucleus and subsequently bind to a DNA sequence known as the androgen response element (ARE) 
(1). Binding of the DHT-AR complex to promoter or enhancer regions of AR regulated genes induces 
the expression of genes implicated in cell proliferation, the inhibition of apoptosis and differentiation (1).  
Androgen action in the prostate effects reciprocal interaction between stromal and epithelial cells to 
maintain normal growth and function (9). Androgens stimulate the stromal cells to secrete peptide 
growth factors known as andromedins, which in turn diffuse into the epithelial cells where they induce 
the expression of genes controlling cell differentiation (7). Concomitantly, androgens also have an 
inhibitory effect on andromedin induced growth in epithelial cells thereby promoting epithelial 
differentiation (7). During carcinogenesis the AR-axis and growth factor network is dysregulated 
resulting in atypical androgen-growth factor interactions. The dysregulation of this network confers a 
selective advantage to malignant epithelial cells by enhancing cell proliferation and invasion ability with 
99% of prostate tumours originating from the prostate epithelium (10).     
1.2 Prostate cancer and associated risk factors 
PCa is the second most prevalent cancer globally with 1.1 million people being diagnosed in 20121. It 
is the sixth leading cause of cancer related deaths accounting for 8% of the total cancer mortalities 
worldwide1. PCa is the most prevalent cancer in South African men with 1 in 23 men being diagnosed 
with the disease2. Incidence rates vary substantially worldwide with the highest rates occurring in the 
western world. The high incidence rate of PCa in western countries coincides with the widespread use 
of biopsies and routine PSA screening tests which results in higher detection of the disease (12,13). 
The rate of diagnosis does not, however, correlate to the number of PCa related fatalities owing to the 
early detection of treatable lower staged cancer (12). Studies have shown that several risk factors 
increase the chances of developing PCa. 
1.2.1 Age 
There is a strong correlation between age and PCa incidence and fatality with over 90% of fatalities 
occurring in men over the age of 65 (12). While men under the age of 50 have only a 0.3% risk of 
developing PCa, the risk increases seven-fold in the next decade and rises sharply to 11.2% for men 
aged over 70. PCa progresses slowly and is preceded by asymptomatic prostate neoplasia which is 
often incidentally revealed during an autopsy. It is predicted that in most cases these localized and 
                                                          
1http // www.cdc.gov/cancer/international/statistics 
2http // za.movember.com/mens-health/prostate-cancer 
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microscopic sized neoplastic lesions would only have become clinically relevant if men lived beyond 
100 years of age (13). 
1.2.2 Race and ethnicity 
Population based studies have revealed trends between the incidence of PCa and different 
geographical locations. Approximately 75% of new PCa cases are reported in developed nations with 
North America having the highest incidence rate followed by Scandinavian countries. The lowest 
incidence rate occurs in Mediterranean countries and Japan (12). Incidence of PCa also differs 
according to ethnicity within different countries. In the USA for example the incidence of PCa is 1.6 
times higher in African-Americans than Caucasian men (12). Migratory studies have also shown an 
elevated incidence rate for Japanese men who had immigrated to Western countries indicating a link 
between PCa and lifestyle factors. Disparities between PCa incidence and different racial groups may 
be attributed to differences in access to healthcare and genetic factors (2). 
1.2.3 Familial associations 
A family history of PCa is a strong indicator of susceptibility to the disease. There is a 2-3 fold likelihood 
of developing PCa for men with first degree relatives diagnosed with the disease (13). Segregation 
studies have been employed to distinguish environmental factors from genetic factors implicated in 
familial PCa (1). The segregation analysis indicated that Mendelian inheritance of the RNASEL gene 
attributed to cases of familial early onset PCa (1). Expression of the RNASEL gene is pervasive as it is 
implicated in 88% of PCa cases for carriers aged over 85 (1). 
1.2.4 Dietary factors 
Several dietary components including fat, dairy products and red meat have been linked to PCa risk 
(14). High fat intake, especially polyunsaturated fats, have been shown to induce the increased 
production of reactive oxidative species (ROS) by various mechanisms (15). For example, a study of 
fatty acid metabolism revealed α-methyl-CoA remarcase (AMACR) is over expressed in PCa tumours 
when compared to normal prostate tissue. AMACR is a peroxisomal enzyme involved in β-oxidation of 
branched fatty acids and which also produces hydrogen peroxide, a highly oxidative carcinogen, as a 
by-product. Dairy products are rich in dietary branched fatty acids and this may account for their link to 
PCa risk. Red meat is considered a high risk dietary component due to the production of carcinogenic 
heterocyclic amines generated during cooking. Heterocyclic amines are potent carcinogens also 
implicated in bladder and colorectal cancer (14). 
Certain dietary factors play a protective role resulting in reduced risk and incidence of PCa. Vitamin E 
(α-tocopherol) possesses anti-oxidative properties and inhibits tumour cell growth by inducing apoptosis 
(15). The hormonal form of vitamin D (1-25-dihydroxyvitamin D) reduces the proliferative capacity and 
differentiation of PCa cells (15). Consumption of tomatoes which contain lycopene reduces the risk of 
PCa by 16%. Lycopene is a carotenoid with powerful anti-oxidative properties and has been reported 
to reduce serum PSA in men with localized PCa (14). The trace element selenium shows the most 
potential as a protective dietary element in PCa. Selenium inhibits tumorigenesis by boosting the 
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immune system, inducing apoptosis, scavenging reactive oxidative species and modulating 
testosterone levels (14). 
1.3 Pathobiology of prostate cancer 
Carcinogenesis in prostate tissue is the result of an accumulation of genetic alterations that confer 
unlimited proliferative ability and reduce apoptosis in affected cells. A multitude of molecular pathways 
have been implicated in PCa initiation and progression. Alterations in tumour suppressors, proto-
oncogenes and inflammatory pathway genes negatively impacts on the regulation of cell proliferation, 
growth and apoptosis. 
Phenotypic changes associated with PCa initiation are well characterized and indicate that 95% of 
prostate cancers are adenocarcinomas. Adenocarcinomas typically arise in epithelial cells of glandular 
tissue and acini (16).  
Neoplastic transformation of the epithelial lining of secretory ducts is defined as prostatic intraepithelial 
neoplasia (PIN). PIN can be classified into low grade or high grade PIN based on cytological 
characteristics (17). High grade PIN lesions are considered a precursor to malignant PCa as they are 
co-localized in the peripheral zone with adenocarcinomas (18). Additionally, high grade PIN shares 
similar atypical genetic alterations and aberrant molecular pathways also observed in adenocarcinomas 
(19). Individuals with PIN are likely to develop PCa within ten years of detection (16).  
Inflammation is a physiological response to tissue damage that facilitates and initiates the healing 
process. However, a chronic inflammatory state particularly in prostate tissue is thought to play a role 
in PCa development and progression (19). Immune system cells recruited during the inflammatory 
release highly reactive molecules such as nitic oxide and hydrogen peroxide (19). These reactive 
chemical species cause damage to the DNA of proliferating epithelial cells resulting in mutagenesis 
(19). Recent studies have identified several genes involved in the inflammatory pathway linked to PCa, 
namely ribonuclease L (RNASEL), macrophage scavenger receptor-1 (MSR1), interleukin-8 (IL-8) and 
vascular endothelial growth factor gene (VGEF) (20). The RNASEL gene encodes a ribonuclease that 
triggers apoptosis on the onset of a viral infection (2). This pro-apoptotic function of RNASEL qualifies 
it as a prostate tumour suppressor gene and its defective form is hence linked to PCa (20). The MSR-
1 gene encodes a transmembrane receptor expressed by macrophages that binds several ligands such 
as gram-negative and gram-positive bacteria, lipoproteins and polynucleotides (21). MSR-1 is 
commonly found at sites of inflammation in the prostate. IL-8 is a cytokine that initiates and amplifies 
the inflammatory response. It has been suggested that the multitude of upstream signalling pathways 
activated by IL-8 promote malignant cell proliferation, metastasis and angiogenesis in endothelial cells 
(22). The VGEF gene encodes a growth factor that is considerably elevated in the plasma of PCa 
patients. VGEF possesses angiogenic properties and is known to promote endothelial cell proliferation, 
vasculogenesis and cell migration (20). Taken together, inflammation is a complex process that is 
effected by a multitude of genes, many of which may contribute to PCa.      
Tumour suppressors are molecular regulators of cell proliferation that inhibit malignant cell growth. 
Inactivation, deletion or suppression of tumour suppressor genes therefore promotes tumour cell 
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proliferation. Several tumour suppressor genes have been identified which when defective contribute 
to PCa, these include retinoblastoma-1 (RB-1), CDKN2A and PTEN genes (23). The RB-1 gene inhibits 
tumorigenesis by arresting the progression of the cell cycle. Suppression of RB-1 has been linked to 
abnormal AR activity, a major contributing factor to castration resistant prostate cancer (CRPC) (24). 
Deletions in the CDKN2A gene are common in several types of cancer and this can be attributed to the 
prominent role it serves as a negative regulator of the cell cycle (23). Mutation of the PTEN gene, 
specifically mono allelic gene loss occur in 60% of localized PCa while homozygous deletions are 
common in CRPC and metastatic PCa (25). PTEN is therefore the most common defective tumour 
suppressor gene linked with PCa. Inactivation of the PTEN gene results in accumulation of PIP3, a 
major substrate for the Akt pathway resulting in evasion of apoptosis and activation of cell survival 
mechanisms (18). The PTEN regulated pathway has therefore become a target of therapeutic agents 
in advanced PCa (23). Another gene commonly silenced during PCa is GSTP1 which encodes the 
enzyme glutathione S-transferase. Hypermethylation of the GSTP promoter region nullifies gene 
expression (23). This epigenetic event has been observed in 90-95% off cancer lesions and 70% of 
high grade PIN lesions (19). GSTP is a carcinogen detoxifying enzyme that removes electrophiles and 
oxidants that cause DNA damage (19). Inactivation of this enzyme increases the susceptibility of DNA 
in prostate tissue to damage caused by ROS resulting in accumulation of mutations associated with 
cancer initiation and progression (23). Methylation of the GSTP1 promoter region is now commonly 
used in as a biomarker during the diagnosis of PCa (23). 
Proto-oncogenes encode proteins that control cell proliferation and apoptosis, and as such alteration in 
these genes initiate and contribute to the amplification of adenocarcinomas (26). Point mutations, gene 
amplifications and chromosomal translocations are three mechanisms by which proto-oncogenes are 
converted to oncogenes. The first mechanism results in a gain of function which sees the proto-
oncogenes being constitutively activated. The remaining mechanisms result in the overexpression of 
the encoded oncogenes. The consequence of these alterations is continuous signalling which induces 
uninhibited cell proliferation. Some of the oncogenes associated with PCa include ERB-2, BLC-2, and 
TMPRSS2-ERG (23). ERB2 encodes a transmembrane tyrosine kinase belonging to the EGRF family 
and is involved in cell growth and differentiation. The deletion of the ligand binding domain results in 
constitutive activation of the receptor in the absence of ligand (26). Studies in PCa cell lines have 
revealed that ERB2 is implicated in the activation of the AR during CRPC via an MAPK and c-Jun 
regulated pathway (27). Additionally, ERB2 plays a crucial role in bone metastasis which is associated 
with a poor prognosis for PCa patients (27). BCL-2 is an anti-apoptotic factor that promotes neoplastic 
cell proliferation by inhibiting the cellular stress response pathway (26). BLC-2 encodes a cytosolic 
protein that is localized to the mitochondria where it inhibits the activity of caspases that induce cell 
death. The overexpressed of BLC-2 in PCa therefore allows malignant cells to by-pass apoptosis. (28). 
Continual chromosomal translocation occurs during prostate cancer and often results in the TMPRSS2 
gene fusing with the ERG gene (27,28). This genomic rearrangement concomitantly results in the 
activation of ERG which belongs to the ETS family of transcription factors (26). Activated ETS related 
transcription factors are involved in promoting proliferation, inhibiting apoptosis, expression of 
Stellenbosch University  https://scholar.sun.ac.za
7 
 
oncogenes and cell migration (27). Therefore, gene fusion of TMPRSS2 and ERG in prostate tissue 
promotes malignant transformation.  
The AR is a steroid hormone nuclear receptor that plays a pivotal role in PCa initiation and development 
(29). In the normal prostate gland the AR binds its native ligands DHT and testosterone which promote 
growth and normal function (33,34). Studies have revealed that 80-90% of PCa is initiated by androgen 
stimulated signals that promote growth and evasion of apoptosis  (34,35). Disruption of the AR pathway 
is therefore the primary endocrine therapy used for PCa treatment (29). This is accomplished by 
reducing the production of testosterone by the testes and/or the inhibition of the AR (30). Androgen 
suppression is initially achieved by surgical or chemical castration (androgen deprivation therapy) (29). 
This is followed by anti-androgen therapy which makes use of non-steroidal AR antagonists such as 
flutamide or bicaluatamide to inhibit the binding of androgens to the AR (31). Both treatment regimens 
are often implemented simultaneously and usually result in remission of the cancer. However, after 1-
3 years the cancer often returns and is then known as CRPC (18). Despite the depletion of serum 
testosterone the AR is thought to mediate tumour progression through several alternative mechanisms. 
First, amplification of the AR gene is thought to increase sensitivity of the AR to low androgen levels. 
Second, mutation of the AR gene may promote promiscuity of the AR such that it is activated by anti-
androgens or non-steroids. Third, dysregulated cytokine or peptide growth pathways may cause 
irregular activation of the AR. Fourth, altered expression of AR coactivators may affect AR ligand 
specificity in such a manner that it is activated by adrenal steroids and non-steroids (22,35). Finally, AR 
expression and signalling resumes due to changes in the intratumoral expression patterns of key 
steroidogenic enzymes, which enables CRPC tissue to convert adrenal androgen precursors such as 
DHEA and androstenedione, which have low androgenic activity, to more potent androgens such as 
testosterone and DHT (32).  
The study of molecular pathways involved in carcinogenesis and tumour progression aids in the 
identification of targets for anti-cancer drug development. Targeted therapy shows immense potential 
as a remedy to PCa as it directly inhibits tumour cell growth and survival. Therefore, elucidation of the 
precise molecular pathobiology of PCa may offer insights on the mechanisms of carcinogenesis and 
present targets for therapeutic intervention. 
1.4 Screening and diagnosis of prostate cancer  
Early stage PCa is not associated with any discernible symptoms. These only manifest during the later 
stages of the disease. It is therefore imperative to diagnose PCa in the early stages when therapeutic 
intervention increases the chances of a favourable clinical outcome. Screening for PCa is normally 
carried out in men over the age of 49 years and in men exhibiting symptoms of lower urinary tract 
symptoms (LUTS) (33). The screening procedure utilizes a PSA blood serum test, palpitation of the 
prostate to detect physical abnormalities via digital rectal exam (DRE) and a transrectal ultrasound 
(TRUS) guided biopsy for histopathological staging of prostate tissue (34).  
 
The PSA test measures the serum levels of PSA and is often used in conjunction with the DRE. The 
use of the PSA test in tandem with the DRE improves the detection rate by 81% (33). A PSA reading 
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above 4 ng/ml indicates the potential presence of PCa and warrants a subsequent biopsy (34). 
However, PSA is a poor diagnostic tool as it fails to distinguish malignant tumours from benign tumours 
thus resulting in overtreatment (35). The lack of specificity of the PSA test results in 30% of patients 
with PCa having normal PSA readings while 20% of patients without PCa have elevated PSA readings 
(33). While the PSA test is a biochemical evaluation, the DRE is a physical examination of the prostate 
gland. During the DRE a gloved finger is inserted into the rectum and the prostate is physically examined 
for firmness, nodularity, asymmetry and induration (36). Following the preliminary screening, an 
abnormal PSA test and DRE warrant subsequent histopathological analysis of prostate tissue. A TRUS 
guided needle is used to extract cells from the transition and peripheral zone of the prostate (2). These 
prostate biopsy samples are assed for the presence of neoplastic cells and the degree of differentiation 
on the basis of the Gleason grading system (figure 1.3) (37). 
Diagnosis of PCa is based on the preliminary imaging of the prostate by TRUS or MRI, determination 
of prostate volume and histological analysis of prostate tissue (2). Malignant tumours are hyperechoic, 
asymmetrical and dilated when compared to healthy prostate tissue (38). These anomalies can be 
visualized by the use of TRUS or MRI and on the basis of the results a biopsy of abnormal tissue is 
carried out (2). An ultrasound guided needle biopsy is performed transrectally via a spring loaded needle 
gun (39). The biopsy samples that are obtained are evaluated for PCa stage using histological analysis 
with reference to the Gleason grading system. The Gleason grading system is based on the glandular 
differentiation and growth patterns of malignant cells in prostate stroma as visualized under a low to 
medium power microscope (38,40). The degree of differentiation is stratified into 5 grades ranging from 
1 to 5 which increase from well differentiated to poorly differentiated tissue architecture (3,40). Due to 
the heterogeneity of PCa the prostate usually contains two or more differentiation patterns. The two 
most prevalent patterns, primary and secondary differentiation patterns are summed to obtain the 
Gleason score which ranges from 2 to 10 (3,40). The Gleason score therefore provides a prognosis 
which is then used to implement appropriate treatment strategies.     
 
 




Figure 1.3: Gleason grading histological score showing progressive loss of prostatic glandular 
differentiation. Modified with permission from Humphrey P., 2004 (37).  
1.5 Prostate cancer treatment  
Several treatment strategies are used to treat PCa and are dependent on patient age, tumour stage 
and physical health. Implementation of the correct treatment therapy is crucial, but is challenging due 
to the highly variable prognosis of PCa.  
 
For localized PCa, watchful waiting, radiation therapy and prostatectomies are the typical routes of 
treatment (16). A radical prostatectomy involves the surgical removal of the prostate gland (12). 
Excision of the prostate may be performed trans-urethrally through the tip of the penis or 
laparoscopically through incisions that are made in the abdomen. The laparoscopic treatment method 
is relatively less invasive to trans-urethral prostate resection especially when it is performed with robotic 
guides. Radical prostatectomy poses numerous harmful side effects with a 50% risk of erectile 
dysfunction, urinary incontinence, infection and excessive bleeding at the site of surgical incisions (12).  
Following removal of the primary tumour through prostatectomy radiotherapy is routinely implemented 
as a follow up treatment and may be administered post-operatively as “adjuvant therapy” or as salvage 
therapy if PSA levels become elevated again. Studies have shown that early radiation therapy results 
in more favourable prognostic outcomes, hence adjuvant therapy is superior to salvage therapy (40). 
Radiotherapy may be further categorized on the basis of radiation delivery method into external beam 
radiation or internal radiation (brachytherapy) 3. External beam radiation makes use of x-rays or gamma 
rays propagated from a linear accelerator to kill tumour cells. This type of radiotherapy is usually 
administered for 6-10 weeks and may be enhanced by ancillary use of computed tomography imaging 
for precise targeting of tumours (2). In brachytherapy, small radioactive pellets (125I or 103Pd) are 
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implanted directly into tumours allowing for high ionization dosage delivery with minimal cytotoxic effects 
on proximal cells (2). The pellets deliver low level x-ray radiation which incidentally can only travel short 
distances thereby limiting the cytotoxic ionization energy to the targeted tumour. Both external beam 
radiation and brachytherapy carry several undesirable side effects such as urinary incontinence, 
irritation of the rectum, erectile dysfunction and fatigue3. Side effects of radiotherapy used as a primary 
treatment are relatively less severe when compared to radical prostatectomy3.To avoid the undesirable 
side effects of both prostatectomies and radiotherapy watchful waiting can be considered as an 
alternative. Using this strategy, clinical symptoms are closely monitored and therapeutic agents are 
administered correspondingly (12).  
Androgen deprivation therapy is the gold standard for treatment of aggressive metastatic PCa. This 
therapy drastically reduces the levels of circulating testosterone, by inhibiting testosterone production 
in the testes by surgical (orchiectomy) or chemical castration, thereby halting the growth and 
proliferation of tumour cells (12). Luteinizing hormone-releasing hormone (LHRH) agonists are synthetic 
peptides that inhibit the production of luteinizing hormone (LH) in the pituitary gland. The reduction in 
LH removes the stimulus for the testes to produce testosterone. LHRH agonists are administered 
subcutaneously and usually comprise either leuprolide acetate or goserelin acetate (2). Seventy percent 
of patients initially respond well to this treatment up until the disease progresses to CRPC. Two drugs, 
abiraterone and enzulatamide have recently been approved for the treatment of metastatic CRPC as 
both significantly increase life expectancy. Abiraterone inhibits androgen biosynthesis by inhibiting 
cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1). The inhibition of CYP17A1 results in a 
considerable decrease in the levels of circulating androgens and androgen precursors. Enzulatamide 
disrupts the AR signalling axis at three junctions: specifically inhibition of nuclear translocation of the 
AR into the nucleus; blocking the AR binding to the DNA; and inhibiting recruitment of co-activators. 
Patients with CRPC have a poor prognosis and at this stage treatment is only palliative (12). 
Chemotherapy, using drugs such as docetaxel and paclitaxel are also used for the treatment for CRPC. 
These drugs do not preferentially target tumour cells and are therefore only used as a last resort to treat 
symptoms of terminal CRPC (2). 
1.6 Benign Prostatic Hyperplasia 
BPH is a urological disease characterized by an increase in cellular proliferation of the stromal and 
glandular components of the prostate gland (41). This condition is non-malignant, but causes an 
increase in size of the prostate. BPH is the most common benign tumour in men affecting one third of 
men between the ages of 50-60 and approximately 90% of men aged 85 and above (42).  
1.6.1 Epidemiology of BPH 
Several risk factors predispose men to developing BPH, namely age, race, familial history and diet (43). 
Prevalence of BPH increases with age with approximately 40% of men aged 50 and 90% of men aged 
                                                          
3 http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-treating-hormone-therapy 
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over 80 exhibiting microscopic BPH (43). Microscopic BPH is usually asymptomatic as only 25-50% of 
cases present clinically relevant (macroscopic) manifestations (44). A study in the USA showed that the 
incidence of BPH was greatest in African Americans and the lowest in Asian (Chinese and Japanese) 
immigrants much like in PCa (44). Another case study in Italy showed a link between dietary habits and 
the risk of BPH (45). Dietary fat derived from dairy products was found to increase risk of BPH while 
lycopene found in tomatoes seemed to play a protective role, presumably due to its antioxidant 
properties (45,46,47). Familial history, specifically inherited genetic polymorphisms of the SRD5A2 
gene is linked to an increased risk of BPH (43). Single nucleotide polymorphisms of the SRD5A2 gene 
cause dysregulation of the SRD5A2 enzyme which contributes to the pathological state of the androgen 
dependent prostate gland observed in BPH (47). More epidemiological studies need to be conducted 
to gain deeper insights into the hormonal changes and the influence of the environment in BPH risk. 
1.6.2 Pathobiology of BPH 
The molecular aetiology of BPH is a multifactorial abrogation of pathways related to tissue remodelling 
of the ageing prostate, hormonal changes and chronic inflammation in the prostate (48). The 
pathogenesis of this disease is not clearly defined and is therefore attributed to these several factors. 
Further evidence of the multifaceted pathobiology of BPH is shown by the cytological and morphological 
variation seen in BPH tissue specimens (43). 
 
Tissue remodelling of cells in the transition zone of the prostate gland is a typical consequence of ageing 
in males. Basal cells undergo the greatest age related modifications of all cell types in the prostate. 
Gradual alterations in intracellular metabolism results in the enlargement and cellular hypertrophy of 
these cells (48). Alteration of prostate epithelial cells sees this cell type adopt a “senescent phenotype” 
resulting in atypical responses to growth factors and other signalling molecules (43). Furthermore, the 
aberrant interaction of epithelial cells and complex signalling pathways disrupts epithelial-stromal 
interactions causing an increase in prostate volume (48).   
The dysregulation of peptide growth factor secretion that occurs in BPH stimulates epithelial and stromal 
cell growth (figure 1.4) (43). Several fibroblast growth factors (FGF) are also known to be overexpressed 
in BPH where they play a growth stimulatory role. FGFs are produced in response to the localized 
hypoxic conditions created by increased cell proliferation in the prostate (49). Stromal cells produce 
FGF-2, -7 and 10 which stimulate epithelial cell growth (43). Epithelial cells in turn produce ILα-1 and 
IL-8 which stimulates the production of FGF-2 and -7 in stromal cells (44,50). FGF-2 is also know to 
promote the growth of stromal components. Taken together, two positive paracrine loop promote 
cellular growth in BPH. 
Cell growth in the healthy prostate is tightly controlled by cellular mechanisms that balance apoptosis 
and cell proliferation. Dysregulation of pathways involved in these two processes is thought to be a 
causative factor in the development of BPH. The proto-oncogene BCL-2 and the growth factor TGFβ 
are known to play pivotal roles in the apoptotic pathway in prostate tissue (43). BCL-2 is an inhibitor of 
apoptosis that is overexpressed in the prostatic epithelium of BPH patients (43). This anti-apoptotic 
molecule is also overexpressed in PCa and other types of cancer further highlighting its prominent role 
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in abnormal cell proliferation.  TGFβ is a negative growth factor that plays a dual role as an inhibitor of 
epithelial cell growth and a promoter of stromal cell differentiation (43). Similar to BCL-2, TGFβ is 
overexpressed in BPH and this may account for the increased smooth muscle tone that is seen in BPH 
patients (43). 
1.6.3 Pathogenesis and clinical presentation 
BPH typically originates in the transition zone adjacent to the prostatic urethra (43). The onset of 
hyperplasia is characterized by the formation of nodules which initially compress prostate tissue (50). 
Progressive nodular proliferation results in compression of the prostatic urethra which in turn causes 
bladder outlet obstruction (BOO) (51). Obstruction of the bladder causes urinary voiding problems, 
bladder hypertrophy and overactive bladder syndrome (42). The clinical manifestation of BOO presents 
varied symptoms among patients collectively termed lower urinary tract symptoms LUTS (52). 
Approximately 25% of men suffer from LUTS with symptoms ranging from mild to severe (53) LUTS 
are characterized by chronic retention, hesitancy, nocturia, dysuria, incomplete voiding and overflow 
incontinence (42). In addition to BOO, symptoms of LUTS may also be attributed to detrusor over 
activity and increased prostatic smooth muscle tone (41).  
1.6.4 Diagnosis and treatment of BPH 
The diagnosis of BPH relies on a physical examination by DRE and subsequent PSA testing if 
necessary. The DRE determines the prostate size, surface texture and symmetry all of which are 
evaluated to assess the risk of BPH (42). A PSA test and TRUS guided biopsy are performed to rule 
out PCa following a DRE which indicates an abnormal prostate. The use of PSA remains controversial 
as it is elevated in a number of pathological states of the prostate including BPH. A urologist may 
sanction further tests to confirm enlargement of the prostate namely, uroflowmetry, residual volume 
measurements and urodynamics (50). Uroflowmetry measures the speed of urination relative to time 
and is used to determine the presence of an obstruction. The residual volume is measured subsequent 
to urine voiding via an abdominal ultrasound. It is used to determine the best treatment course with a 
volume above 300 ml indicating acute urinary retention and necessitating surgery. Urodynamics are 
employed when an obstruction is not clearly detected and gives predictive information for the best 
treatment course. Urondynamics measure both pressure and flow rate, and is used to distinguish 
between bladder obstruction and detrusor instability (50). 
 
Treatment for BPH is used to relieve the symptoms of LUTS, improve the overall quality of life of the 
patient and prevent complications that may arise from LUTS. Depending on the severity of LUTS 
treatment may be pharmacological or surgery based (54). Pharmacological treatment is usually 
prescribed to men presenting mild to moderate symptoms and includes SRD5A inhibitors and α-
blockers (54). α-blockers are the first line of treatment for mild LUTS and effect their mode of action by 
binding the α1 adrenoreceptors in the prostate (54). This  relaxes smooth muscle in the prostate and 
bladder neck thereby improving urine flow (42). The SRD5A inhibitors prevent the conversion of 
testosterone to DHT by SRD5A (42). This reduces prostate size by 20-30%, improves urine flow and 
prevents secondary complications of  LUTS such as acute urinary retention (54). Surgical treatment is 
Stellenbosch University  https://scholar.sun.ac.za
13 
 
reserved for patients with severe LUTS or complications thereof such as haematuria, acute urinary 
retention, renal failure and bladder stones (53). The most commonly used surgical procedure is the 
transurethral resection of the prostate (TURP). This method sees hyperplastic tissue being excised from 
the bladder neck and has a success rate of 80% (41). To conclude, BPH is a complex disease and 
progress is being made to improve diagnosis and provide non-invasive treatment options that improve 



























Biomarkers can be defined as alterations of cellular biochemical processes resulting in quantifiable 
changes in body tissue, cells or fluids which are unique to pathological or physiological processes 
(56,57). The myriad of cell types in the body possess unique molecular signatures which are altered 
during disease states (57). Detailed knowledge of this molecular signature under normal physiological 
conditions may be key to unlocking the precise mechanism of disease aetiology. Consequently, a 
biomarker may be used to measure specific parameters that are indicative of an abnormal state (57). 
Aberrations of the genome caused by somatic or germline mutations may result in an altered phenotype 
which is reflected in the atypical expression of genes, metabolic pathways and proteomic signatures 
(58). Therefore, the primary utility of biomarkers is to measure and assess the normal and pathologic 
state as well as determine the response to therapeutic intervention (57,60) . One such example is the 
urine test for glucose used to identify patients suffering from diabetes. The dysregulation of metabolic 
pathways involved in sugar metabolism results in elevated blood-glucose subsequent excretion in the 
urine where it is detected (60). 
 
A biomarker may also be defined as a specific physical, chemical or biological feature that characterizes 
processes occurring in living organisms. Biomarkers render insights into the biochemical pathways 
connected to pathogenesis which allows disease progression or regression to be tracked (56). This 
definition deviates from the steadfast interpretation of biomarkers as biological entities and incorporates 
high throughput techniques such as MS and NMR that aid in defining pathogenesis and monitoring its 
development at the cellular level (55). For this purpose, biomarkers are prone to modulation and 
therefore increase our knowledge of drug pharmacodynamics (57).  
1.7.1 Cancer Biomarkers 
Cancer is a multi-faceted disease defined by irreversible alterations of the genomic framework and gene 
expression. Modifications in three subsets of genes, namely oncogenes, tumour suppressor genes and 
DNA repair genes consequently results in the cellular machinery by-passing the usual biological 
regulatory system (61). This distinct genotype bestows a survival advantage to the expressed 
phenotype due to the dysregulation of specific cell cycle checkpoints (57). The genetic diversity of the 
disease is reflected in the clinical setting where the pathogenicity and aggressiveness of the disease 
varies across individuals. Consequently, these variations present a formidable problem in the treatment 
of the disease especially when it is in its advanced stages (62). A key factor in the successful treatment 
of cancer lies in early detection of the disease when tumour progression can be halted (59). The 
progression of a normal cell into a malignant tumour cell is a complex process defined at each stage by 
aberrant cellular biochemistry. These aberrant molecular signatures may indicate hyperproliferation, 
gene over expression, abnormal gene expression, inflammation, hyperplasia or atypical enzymatic 
activity (61). Therefore, by deciphering the complex molecular signature of malignant transformation, 
biomarkers can be utilized as early indicators of cancer or risk thereof (59). 
 
A cancer biomarker refers to a quantifiable biological molecule localized in body tissue or fluids that 
serves as an indicator of a malignant tumour. These biomarkers are produced either by the tumour or 
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host tissue in response to the tumour (57). Cancer biomarkers play a pivotal role in the early detection, 
screening, prognosis, disease staging and prediction of therapeutic intervention (60,62). They may be 
measured either quantitatively or qualitatively, and span many different forms such as nucleic acids, 
proteins, metabolites, or cellular events associated with proliferation or angiogenesis (3,63). These 
biomarkers may be present in the blood, cerebrospinal fluid, urine, saliva, or tissue samples (56,62).  
The first recognized cancer biomarker was reported in 1965 (Table 1.1) by Dr Joseph Gold based on 
his investigation of tumour specific antigens associated with colon cancer. He identified a protein in the 
blood of colon cancer patients normally found in fetal tissue and accordingly named it carcinoembryonic 
antigen (CEA) (64,65). Gold’s research laid the foundation for advancement in this field with the 1970’s 
being notable for a variety of serum tests developed for numerous types of cancers. The 1980’s saw 
even more remarkable progress with the introduction of biomarkers for colorectal, pancreatic cancer 
(CA19-9), ovarian cancer (CA-125) and breast cancer (CA15-3) (64). At present the most well-known 
biomarker, commonly utilized for prostate cancer screening tests is the prostate specific antigen (PSA). 
PSA was first characterized in 1979 and later approved for monitoring PCa in 1986 by the United States 
Food and Drug Administration (FDA) (66,67). The PSA blood test for monitoring PCa progression 
provided a major boost for treatment of PCa patients. The greatest utility of PSA as a biomarker however 
was discovered after a study by Catalona et al. reported elevated PSA serum levels in asymptomatic 
men (67,68). Following this study PSA was approved as a PCa screening tool in 1994 by the FDA and 
has since significantly reduced PCa induced mortality (67). The drawback of PSA as with most of the 
fore mentioned cancer biomarkers is its lack of specificity which causes misdiagnosis. In brief, these 
biomarkers serve as indicators of cancer since they are present at the conventional basal level in normal 
individuals and significantly elevated in cancer sufferers. Limited progress has been made in the 
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Table 1.1 Cancer biomarkers that are in current use. DRE, digital rectal examination; ER, estrogen 
receptor; NACB, National Academy of Clinical Biochemistry; NSGCT, nonseminomatous germ cell; 
PgR, progesterone receptor. Reproduced from Kulasingam et al., 2007 (69). 
Tumor Marker Cancer Type Year of Discovery Application based on 
ASCO and /or NACB 
recommendations   
α-fetoprotein Germ-cell hepatoma 1963 Diagnosis 





















CA 19-9 Pancreatic 1979 Monitoring therapy 
 
Carcinoembryonic antigen Colon 1965 Monitoring therapy 
Prognosis 




ER and PgR Breast 1970s Select patients for 
endocrine therapy 
 
HER2 Breast 1985-6 Select patients for 
trastuzumab therapy 
 
Lactate dehydrogenase Germ cell 1954 Diagnosis 
Prognosis 
Detecting recurrence  
Monitoring therapy 
 
Prostate specific antigen Prostate 1979 Screening (with DRE) 
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1.7.2 Classification of cancer biomarkers 
Different criteria has been employed to classify cancer biomarkers but no clear-cut standardized system 
has yet been devised. The absence of a conventional classification system can be attributed to the 
plethora of new information coming from the biomedical sciences field coupled to advances in 
technology (59). A simple yet effective method of biomarker classification places emphasis on 
monitoring the progression of the disease (70). This classification system delineates the continuum of 
events that characterize cancer beginning from primary exposure to the advanced metastatic disease 
(figure 1.4). Additionally, this approach may aid clinical processes such as early diagnosis, prognosis 
and prediction of drug efficacy (55). In the clinical setting however, tumour biomarkers will frequently 
overlap in such a manner that they cannot be exclusively designated to a single classification strata 
(59). Therefore, tumour marker classification in this context relies on close observation of the disease 
from the earliest phase up to advanced metastatic cancer (55). Cancer biomarkers classified according 
to the characterization of disease progression can be classified into screening, diagnostic, prognostic, 
predictive, pharmacodynamic and surrogate end-point biomarkers. 
 
 
Figure 1.4:  Cancer initiation and progression. Modified with permission from Srinivas et al., 2001 (61). 
 
Screening (Early Detection) Biomarkers 
Screening biomarkers are used to identify individuals at risk of developing cancer in an asymptomatic 
population. They essentially serve as an early warning system for individuals at high risk of developing 
cancer. Caution must be exercised before the sanctioned use of these biomarkers as the benefit of 
early detection must outweigh the risk of erroneous diagnosis (71). 
 
 




The ideal diagnostic biomarker possesses a high level of sensitivity and specificity (71). According to 
Maruvada et al. sensitivity is defined as “the true-positive test results expressed as a percentage of all 
tested individuals who have that disease” while specificity is defined as “true-negative results expressed 
as a percentage of all tested individuals who do not have that disease” (72). 
Prognostic biomarkers 
Prognostic biomarkers are utilized when clinical manifestation of cancer have been established (63). 
These biomarkers aid in predicting the likely course of neoplastic progression, recurrence and therefore 
assist oncologists in selecting appropriate treatment methods (60,63). They may also be selected based 
on histopathological grading of tumours which enables differentiation of malignant tumours from benign 
tumours (59).  
Predictive/stratification biomarkers 
Predictive biomarkers are utilized for evaluating the effectiveness of a particular treatment for an 
individual (60,63). They are typically derived from the analysis of the gene expression profile of the 
specific cancer type (63). Knowledge of the molecular profile of the specific tumour makes it possible 
to predict the outcome of the chemotherapeutic drugs that will be administered (59). 
Pharmacodynamic biomarkers 
Pharmacodynamic biomarkers can predict the effect of a drug on a biological system. These molecular 
markers can be used to evaluate the relationship between treatment modality, target response and 
closely related molecular pathways that may be affected. Single-molecule real-time sequencing, ion 
torrent sequencing and nanopore sequencing (discussed in section 1.8.1) are tools used to elucidate 
pharmacodynamic biomarkers. Pharmacodynamic biomarkers can be used in oncology to identify 
effective drug combinations and schedule for different treatment regimens to be implemented (73). 
Surrogate end-point biomarkers 
Surrogate end-point biomarkers are useful for the observation of patient response to a particular type 
of treatment (71). This type of biomarker provides a holistic outlook of disease progression which can 
be used to predict the end-result of the chosen treatment. Indeed surrogate end-point biomarkers serve 
as interim clinical endpoints and their predictions determine the potential benefit or harm the proposed 
treatment (74). 
1.7.3 Current and potential biomarkers for prostate cancer 
The process of malignant transformation in prostate cells is characterized by aberrant genomic 
alterations that confer unlimited proliferative capacity, angiogenesis, evasion of apoptosis and 
metastatic capability as discussed in section 1.3 (75). Pathways involved in these oncogenic events 
together with proliferation signalling molecules have been identified as key targets for biomarker mining. 
The implementation of a novel biomarker at the clinical level has thus far been confounded due to the 
heterogeneity of PCa caused by the multitude of genetic alterations (51).  As a result there is a growing 
consensus to identify a panel of biomarkers that can be used to detect early stage PCa and inhibit its 
progression to late stage CRPC (75). At present potential molecular markers are primarily being 
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investigated in serum and tissue. Molecular signatures unique to tumour cells are also being 
investigated (51). The utility of these emerging PCa biomarkers include screening, staging, assessing 
metastatic potential and prognosis (75). 
1.7.3.1 Serum biomarkers 
Serum biomarkers are molecules produced by tumour cells or proximal cells in the tumour 
microenvironment (76). These molecules are released into circulation and can be measured using 
diagnostic assays. Serum biomarkers are gaining widespread utility in the clinical setting as they can 
be obtained economically and in a non-invasive manner. Currently the serum biomarker PSA is used 
for screening and staging PCa (75). It has however come under criticism as it is elevated in serum 
during benign prostate pathologies such as BPH and acute prostatitis (77). Therefore new biomarkers 
and PSA derivatives have been proposed as alternatives to increase specificity and distinguish between 
aggressive cancer and indolent cancer (77). 
1.7.3.1.1 Prostate Specific Antigen 
The measurement of total prostate specific antigen (tPSA) in blood serum is the standard clinical 
practice for screening, monitoring and predicating outcome of therapy in PCa patients (78). The 
concentration of tPSA in serum is determined by the total number of cells producing PSA, expression 
of the PSA gene and the extent of leakage into circulation from disrupted cell architecture (78). 
Screening tests for PCa that employ tPSA serum measurement have a positive predicative value as 
low as 25% for patients with readings between 4-10 ng/ml (79). The relationship between tPSA and 
PCa remains unclear as evidenced by its poor predictive value for disease screening. Total PSA offers 
greater value as a prognostic tool and is often employed to predict outcome of radical prostatectomy 
such as tumour volume and disease stage (80). Total PSA can also be used to monitor patients on 
hormone therapy for late stage PCa. After a 7 month treatment period serum tPSA falls to a nadir level 
that can be interpreted to give an accurate prognosis (78). A tPSA reading above 4 ng/ml is associated 
with a poor clinical outcome whereas a reading below 0.2 ng/ml indicates a favourable prognosis4.  
 
The lack of specificity of PSA as a biomarker has led to the investigation of its derivatives as alternatives, 
these include free-to-total PSA ratio, PSA density, PSA velocity and PSA isoforms (75). Free-to-total 
PSA ratio can be used to enhance specificity for patients with a tPSA reading between 4-10 ng/ml (75). 
A relatively lower free-to-total PSA ratio is associated with PCa; a ratio between 0-10% carries 55% risk 
of PCa while a ratio greater than 25% carries only a 8% risk of PCa (78). PSA density is determined by 
dividing serum tPSA by prostate volume and is thought to aid in differentiating early stage PCa from 
BPH (74,77). The amount of PSA released into serum in PCa is relatively higher when compared to 
PSA serum levels associated with BPH (75). Therefore, a high PSA density is associated with PCa 
while a lower PSA density is indicative of BPH. PSA velocity is a measure of serum PSA over a given 
time period and is reflective of the physiological state of the prostate (78). A PSA velocity greater than 
                                                          
4 https://www.auanet.org/education/guidelines/prostate-specific-antigen.cfm 
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0.75 ng/ml/year increases the likelihood of diagnosing PCa while it is in its early stages (78). Recent 
investigations have identified PSA isoforms, namely BPH specific PSA (BPSA) and pro-PSA as 
promising biomarkers with an enhanced ability to differentiate PCa from BPH (75). 
1.7.3.1.2 Human Kallikrein-Related Peptidase 2 
Human Kallikrein-Related Peptidase 2 (KLK-2) is a serine protease secreted by the prostate gland that 
functions to convert the precursor form of PSA to active PSA (81). KLK-2 shares an 80% sequence 
homology with PSA and is also present in serum at 2% the concentration of PSA (81). Several studies 
have reported tissue levels of KLK-2 being elevated in PCa and it may thus serve as a biomarker. 
Serum studies have reported the diagnostic utility of KLK-2 when used in combination with free PSA 
and tPSA for disease staging, extracapsular extension and prognosis for patients who have undergone 
radical prostatectomy (63,64). Measurement of complexed KLK-2 (KLK-2-P16) in the serum can 
improve specificity as it has been shown to be associated with prostate tumour tissue (66).  
1.7.3.1.3 Kallikrein-4 (KLK-4)  
KLK-4 is an androgen-regulated serine protease highly expressed in the prostate linked to PCa 
progression (75). Antibodies of KLK-4 are elevated in the serum of PCa patients while tumour tissue 
levels of KLK-4 are relatively higher than in normal prostate tissue (75). The overexpression of KLK-4 
in the prostate during PCa is thought to mediate the transition of cell morphology from epithelial to 
mesenchymal (EMT) conformation (58,66). This transition is caused by KLK-4 mediated reduction in E-
cadherin expression and increased vimentin expression which is a prominent EMT event (75). 
Additionally, PC3 cells that overexpressed KLK-4 showed a considerable increase in cell proliferation, 
motility and colony formation (82). In a study by Gao et al. it was discovered that KLK-4 facilitates 
metastasis by mediating interactions between osteoblasts and tumour cells (82). As the various roles 
of KLK-4 in PCa progression continue to be elucidated, this protease shows immense potential as a 
biomarker for the diagnosis of PCa.  
1.7.3.1.4 E-cadherin  
E-cadherin is a glycoprotein localized at cell junctions that maintain cell-cell adhesion and a connection 
to the encapsulating extracellular matrix (ECM) (74,82). It plays an indirect role in maintaining cell 
quiescence by inhibiting anoikis, cell death caused by detachment of cells from other cells or the ECM 
(75). Serum E-cadherin levels of advanced stage metastatic PCa patients are typically elevated since 
it is detached from cell junctions and free to enter circulation. Another molecular event associated with 
downregulation of E-cadherin is the switching of cadherin type expression to N-cadherin. N-cadherin is 
associated with metastasis, increased invasion capacity and increased mortality risk (75). E-cadherin 
therefore shows potential as a diagnostic PCa tool and a target for therapy in metastatic PCa. 
1.7.3.1.5 Minichromosome maintenance protein (MCM2-7)  
Minichromosome maintenance (MCM) proteins, 2-7 are involved in the initiation of DNA replication and 
maintenance of genomic stability in replicating cells (84). Expression of MCM proteins is linked to the 
cell cycle with upregulation in all phases of the cell cycle except for the G0 phase when they are down 
regulated (84). The crucial role of these proteins in DNA proliferation inevitably links them to 
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carcinogenesis as is seen by the overexpression of MCM-5 in PCa tissue and elevation in the urine 
sediments of PCa patients (58,68). As a consequence of its overexpression in PCa tissue MCM-5 
serves as a prognostic tool for patients receiving radiotherapy, hormonal therapy and radical 
prostatectomy (75). MCM-5 levels are considerably reduced in the prostate tissue of BPH patients 
making it a promising diagnostic tool for differentiating between the benign and aggressive disease 
state. Another protein in the MCM family useful for diagnostic purposes is MCM-7 which can 
differentiate BPH from low PIN and aggressive cancer (75). Further research must be conducted to 
evaluate the clinical utility of these proteins as biomarkers. 
1.7.3.1.6 Early Prostate Cancer Antigen (EPCA-2) 
The nuclear matrix consists of a structural framework that maintains the spatial arrangement of 
components responsible for nucleotide synthesis, steroid transport and nuclear organization (85). 
Alteration of the nuclear matrix proteins is linked with carcinogenesis, most notably early prostate 
cancer antigen (EPCA-2) protein (79). EPAC-2 is a nuclear matrix protein that is exclusively expressed 
in prostate tissue and elevated in the serum of PCa patients (75). This nuclear matrix protein was first 
identified in a study that profiled the proteome of rat prostates. Following this study, a serum based 
assay with 94% specificity and 92% sensitivity was developed (74,79). More recent studies have 
focused on developing anti-bodies against epitopes of EPCA-2 that are simple to detect in serum and 
increase specificity (75). Two epitopes, EPCA-2.19 and EPCA-2.22 have shown promise and could 
potentially be used in tandem to diagnose and stage PCa (75). 
1.7.3.1.7 Interleukin-6 (IL-6)/Interleukin-6 Receptor (IL-6R)  
Interleukin-6 (IL-6) is a cytokine which stimulates the growth of prostate tumours (86). This cytokine’s 
receptor exists in two forms, the membrane bound mIL-6R and the soluble sIL-6R (75). Studies have 
reported the elevation of IL-6 and sIL-6R in the serum of PCa patients (86). Elevated serum levels of 
IL-6 and sIL-6R are linked to tumour aggressiveness, increased tumour volume, metastasis and poor 
survival outcome (76,89). An in vitro investigation that studied the effect of IL-6 and sIL-6 on prostate 
cells by Santer et al. reported increased cell motility, migration and reduced adhesion (75). IL-6 and 
sIL-6R have shown potential as biomarkers for PCa and have already been incorporated in a panel of 
biomarkers as prognostic tools for radical prostatectomy (75). 
1.7.3.1.8 Prostate Cancer Gene 3 (PCA3)  
The prostate cancer antigen gene (PCA3) was first reported by Bussemakers et al. as a non-coding 
RNA that is overexpressed in 95% of PCa cases (88). PCA3 is upregulated approximately 66-fold in 
PCa tissue relative to normal prostate tissue and can thus serve as a viable biomarker (78). Its reliability 
as a biomarker is evidenced by a commercial testing kit, APTIMA®  PCA3 for measuring urine levels of 
PCA3 (80). Also, a comparative study of PCA3 and PSA as first line screening tools for PCa showed 
that PCA3 was better suited to identifying early stage PCa than PSA (75). For these reasons PCA3 is 
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1.7.3.2 Tissue biomarkers 
Prostate biopsies are a rich source of biomarkers and have recently started finding clinical utility due to 
advancements in immunohistochemistry, tumour microarrays and imaging technologies (89). 
Immunohistochemical staining antibodies bind biomarkers in solid tumour samples uniformly while 
tumour microarrays facilitate high throughput analysis of multiple samples (89). The combination of high 
throughput analysis and uniform staining enables the analysis of multiple biomarkers on tumour 
samples. Automated image analysis of the stained specimens enables accurate and precise 
quantitation of biomarkers in solid tumours (89). Expression of urokinase-type plasminogen activator, 
prostate stem cell antigen (PSCA) and α-methyl-co-racemase (AMACR) correlate with PCa and are 
being investigated as potential tissue biomarkers (75). 
1.7.3.2.1 Urokinase-type plasminogen activator (uPA) 
Urokinase-type plasminogen activator (uPA) is a serine protease that degrades protein components of 
the extracellular matrix and basement membrane (74,89). This protease is a component of the uPA 
complex which comprises its receptor (uPAR), plasminogen and plasminogen activation inhibitors (PA-
1, PA-2) (90). Urokinase-type plasminogen activator exerts its effects by binding to its receptor which 
activates a signalling cascade that initiates membrane proteolysis via broad spectrum proteases (75). 
The activation of these proteases in tumour cells is associated with metastasis and angiogenesis. 
Immunohistochemical tissue analysis of PCa cells, lymph node metastases, and tumour associated 
stroma cells revealed overexpression of uPA, uPAR and its inhibitor PA-1 (91). In addition to its 
inhibitory role, PA-1 was also linked to tumour related processes such as migration, cell adhesion, 
proliferation and chemotaxis (91). A recent study by Skovgaard et al. described the imaging of malignant 
prostate tissue by positron emission tomography (PET) to generate a quantitative expression profile of 
the uPAR system (91). Urokinase-type plasminogen activator can therefore be used as a tissue 
biomarker for metastatic PCa and an inhibitory target for PCa treatment. 
1.7.3.2.2 Prostate Stem Cell Antigen (PSCA) 
Prostate stem cell antigen (PSCA) is a membrane glycoprotein differentially expressed in prostate 
tissue (80). The function of PSCA in normal physiological processes or carcinogenesis is unknown but 
its expression is elevated in the prostate of PCa patients. PSCA is expressed in 100% of metastasis 
samples and 94% of primary tumour samples (75). The RNA of PSCA has also been detected in the 
serum of PCa patients. The differential expression of PSCA in the prostate makes it an ideal biomarker 
for disease screening and a staging tool to determine the aggressiveness of PCa (80).  
1.7.3.2.3 α-methyl-CoA-racemase (AMACR) 
α-methyl-CoA-racemase is an enzyme involved in the peroxisomal β-oxidation of branched chain fatty 
acids (79). This enzyme is highly expressed in malignant tumour tissue. Immunohistochemical staining 
of tumour tissue for AMACR is able to differentiate PCa from BPH with 97% diagnostic sensitivity and 
92% specificity. AMACR also possesses prognostic value with expression levels being used to 
determine PCa recurrence and survival outcome. This enzyme is has already gained clinical utility as a 
diagnostic tool in combination with other biomarkers (80). 
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1.7.3.3 Molecular signature biomarkers 
The molecular signature of a cancer cell is a characteristic protein or nucleic acid expression profile that 
distinguishes the tumour cell from normal proximal stromal or epithelial cells. High throughput analysis 
of molecular signatures offers insights into classifying cancer heterogeneity, staging, and 
aggressiveness. Delineation of molecular pathways involved in disease progression can provide targets 
for therapy and prediction the outcome of therapeutic intervention. With improvements in technology 
disease patterns can be profiled in individuals to increase diagnostic accuracy and administer 
personalized treatment regimens for patients. The desired outcome of selective therapy is accurate 
disease staging and increased patient survival (61,74).  
1.8 Strategies for discovering novel biomarkers 
The advent of high-throughput technologies aka “omic” technologies has enabled the extensive analysis 
of the molecular biology of the human body. Biomarker discovery is one such field of molecular biology 
that makes use of omics. The high throughput techniques used in these biomarker studies determine 
the data quality and experimental limits of the investigation (92). The powerful analytical capabilities of 
omics instrumentation has led to the widespread use of this technology in cancer biomarker research 
(93). Traditionally the approach used for cancer biomarker research relied principally on genomics and 
ancillary computational tools (92). However, due to rapid advances in high-throughput technology and 
a need for a more holistic analysis of the physiological microenvironment other techniques are now 
implemented to augment genomics data (92). Strategies commonly used to identify cancer biomarkers 
include genomics, proteomics, metabolomics and glycomics. These approaches all share the same 
general statistical principles beginning with preliminary data analysis of samples to reduce experimental 
noise followed by probabilistic calculations to evaluate the link between measured molecular dynamics 
to the disease state (93).Taking it altogether, interpretation of the data generated by omic technologies 
in the drive to find cancer biomarkers can be used to delineate mechanisms of tumour pathology and 
ultimately find effective therapeutic remedies. 
1.8.1 Genomics 
Completion of the Human Genome Project in 2001 ushered in new innovations in molecular biology 
that provided insights into cancer pathobiology (94). The clinical and biological features of the cancer 
phenotype are directly linked to alterations in the genome. Therefore, characterization of the tumour 
genome can be used to reveal and compile the disease causing mutational profile (95). Advances in 
next generation sequencing have made it possible to comparatively sequence the genotype of cancer 
cells and normal cells (96). The two high throughput methods commonly used to decipher genomic 
patterns in biological systems are DNA microarrays and whole genome sequencing (94). 
 
Enhanced throughput utilized in DNA microarrays facilitates the genotyping and sequencing of patient 
tumours with a high degree of sensitivity and specificity (94). DNA microarrays comprise of probe 
sequences affixed to a solid surface that hybridize with fluorophore labelled sample DNA or RNA. The 
probe-DNA/RNA hybrid fluorescence signal is detected by a scanning confocal microscope and 
analysed by software (95,96). A two colour fluorescent tagging technique is often employed to compare 
Stellenbosch University  https://scholar.sun.ac.za
24 
 
different tissue types, normal vs disease state or cell cultures subjected to different treatments (96). 
Whole genome sequencing provides a comprehensive, cost effective and robust method for sequencing 
the cancer genome (98). Using this technique, profiling of the human genome sequence has identified 
inherited DNA variants that increase susceptibility to several cancer types (99). This is the basis of 
genome wide association studies which evaluate the prevalence of these genetic variants across a 
given population (99). Whole genome sequencing employs a number of sequencing tools that provide 
high resolution and increased sensitivity such that even the smallest genetic variants can be detected5. 
Advances in high throughput next generation sequencing technology such as single-molecule real-time 
sequencing, ion torrent sequencing, nanopore sequencing and pyrosequencing facilitate detection of 
single nucleotide variants, deletions, copy number changes, and chromosomal translocations 
(102,103). A multitude of genetic alterations have been identified in the PCa genome, one of the most 
prominent being the differential expression of the AMACR gene. In summary the continuing 
advancements in next generation sequencing will accelerate and simplify the characterization of the 
cancer genome and eventually a central metric can be established to provide gene expression based 
diagnosis, prognosis and offer therapeutic targets (99).                             
1.8.2 Metabolomics 
Metabolomics is an analytical approach that comprehensively studies the entire complement of 
metabolites in a biological system (101,102). In this approach low molecular weight metabolites are 
extracted from easily accessible biofluids and characterized to generate a metabolic responsive profile 
(103). Identification and quantification of metabolites relies on high through-put analytical technologies, 
namely nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) (103). NMR 
provides rapid and non-destructive analysis of primary extracts while generating highly reproducible 
results. Gas chromatography (GC) and liquid chromatography (LC) coupled to MS are alternatives to 
NMR and offer higher resolution and separation reproducibility (103). NMR and MS technologies are 
often used in tandem to maximize the depth of metabolome analysis. Molecular targets of metabolomics 
constitute the metabolome and include lipids, thiols, amino acids, peptides, vitamins, nucleic acids and 
carbohydrates (102). These molecules take part in anabolic and catabolic reactions that sustain growth, 
maintenance and function (104). Therefore, analysis of metabolome can offer insights into molecular 
pathways that are disrupted in the disease state. 
 
The metabolic profile of cancer cells shows enhanced glucose uptake, down regulation of oxidative 
phosphorylation and preferential conversion of pyruvate to lactate to replenish energy lost to 
dysregulated respiratory pathways (104). Several pathways are altered in tumour cells relative to normal 
cells, namely glycolysis, pentose phosphate pathway, tricarboxylic acid (TCA) cycle, nucleotide and 
protein biosynthesis (104). Different approaches may be used to study the metabolites of these altered 
pathways (figure 1.5)  but the most commonly used analytical platforms for cancer research are 
metabolic fingerprinting which identifies and quantifies metabolites, and metabolic profiling which is 
                                                          
5 http://www.illumina.com 
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typically used in tissue comparison analysis (104,105). In a study of PCa biomarkers by Soliman et al., 
urine profiling by CE-ESI-MS/MS presented sarcosine as a potential biomarker (106). 
1.8.3 Glycomics 
Glycomics is a study that aims to characterize the structure and function of the full complement of 
glycans (glycome) produced by a cell or organism (107). Glycosylation is a posttranslational 
modification (PTM) occurring in the endoplasmic reticulum (ER) and Golgi apparatus which entails 
sugar moieties being attached to proteins (108). Approximately 50% of all proteins undergo 
glycosylation which contributes greatly to diversity of the proteome (109). Due to the abundance of 
glycoproteins in serum they are the principal focus for investigations of disease biomarker identification. 
Additionally, glycoproteins are ideal molecules for this analytical platform due to their ideal small size 
which makes them easy to quantitate (107). Extracellular matrices and cell surfaces are the 
predominant sites for glycosylation and this PTM therefore plays a pivotal role in cellular interactions 
(109). There is a considerable difference in the expression of glycosylation between tumour cells and 
normal cells due to the temporal and cell specific glycosylation that reflects the dynamic response of 
the phenotype to stimuli (108). MS based profiling of the glycome for disease biomarker identification 
revealed abnormal expression of  glycosyltransferases and sugar nucleotide donors in tumour cells 
(109). A study by Saldova et al. that characterized the glycosylation of serum glycoproteins showed 



























Figure 1.5: Different metabolomics approaches. Fingerprinting is the generation of a metabolic profile 
incorporating all metabolites in a system under investigation. Footprinting is the analysis of metabolites 
that are external to the system to evaluate metabolic exchange. Profiling is the analysis of a large class 
of molecules with the inclusion of standards. Flux analysis studies production and consumption rates 
of isotopically or radioactively metabolites in a biological system, it also determines the metabolic fate 
of the molecule. Target analysis compares two closely related target metabolites in a system using one 
particular analytical technique for the best performance. Modified with permission from Armitage et al., 
2013 (104). 
 
1.8.4 Proteomics  
Proteomics is a comprehensive study of proteins that quantifies the products of gene expression to 
characterize different biological states and delineate mechanisms of gene expression control (110). 
Initiation and progression of cancer is a multi-step process characterized by abnormal protein 
expression. These proteins can be detected in biological fluids such as saliva, blood or urine and 
analysed to identify PTMs or expression levels associated with a pathological state. Several high 
throughput proteomic technologies such as 2-DE/MALDI-TOF, SELDI/Protein Chip and most recently  
liquid chromatography tandem mass spectrometry (LC-MS/MS) powered by hybrid mass spectrometers 















1.9 Proteomics as a viable platform for biomarker discovery 
Proteomics is a study that focuses on characterizing the entire protein complement of a cell, tissue or 
organism (112). While DNA microarrays have previously been used as the principle tool to analyse 
protein expression (113), mRNA expression levels are not an appropriate proxy for protein abundance. 
Shortcomings of this genomic approach are apparent when considering that there are approximately 
25 000 genes in comparison to almost a million proteins (114). The poor correlation between mRNA 
and protein can be attributed to dynamic mechanistic and regulatory processes which the proteins are 
subjected to (111,112). These include proteolytic degradation, PTM and complex formation. The wide 
array of post translational biochemical alterations that proteins undergo means that their expression is 
temporal and varies markedly in different tissues (115).  
 
The proteins expressed by a cell or tissue are termed the proteome (116). Analysis of any given 
proteome poses a major challenge due to the diversity of protein species that arise from the afore 
mentioned processes (116). Proteomic studies therefore rely on state-of-the-art high-throughput 
technologies to address this complexity. Proteomic techniques uses a variety of techniques including 
various pre-fractionation methods, liquid chromatography, MS and bioinformatics for the accurate 
identification and characterization of proteomes (116). Proteomic approaches can be used for proteome 
profiling or to study protein-protein interactions, the identification of PTMs or for comparative protein 
expression studies and the elucidation of system wide protein networks (111,114,115) . 
MS based proteomics has established itself as a viable platform for cancer biomarker discovery (119). 
Proteomic methods can generate protein profiles of tumour or normal cells in human clinical samples 
such as plasma, serum or urine (116,117). Since proteins are the functional units of expressed genes 
their analysis can offer insights into the pathophysiology of neoplastic transformation (120). The 
transformation of a normal cell into a cancer cell is reflected by distinct features at the protein level such 
as differential expression, altered specific activity, differential protein modification and altered cellular 
localization (61,117). Proteomics can therefore be utilized to elucidate proteins which can potentially 
serve as diagnostic tools for the treatment of cancer. 
1.9.1 Mass Spectrometry 
Mass spectrometry is an analytical technique that measures the mass to charge ratio (m/z) of ionized 
gaseous molecules (121). The mass to charge ratio of each molecule is plotted against the relative 
abundance to yield a mass spectra (122). A basic mass spectrometer consists of an ion source, mass 
analyser and detector (122). The ion source simultaneously ionizes and converts analyte molecules to 
the gas phase. A mass analyser subsequently resolves the analyte molecules according to their m/z 
ratio. The final component of the mass spectrometer is the detector which quantifies gaseous ion 
species corresponding to a m/z value (119,120). The analytical power of the mass analyser rests on 
three principal factors namely, sensitivity, resolution and mass accuracy (119,120). High performance 
mass analysers enable the measurement of analytes down to the femtogram level (122).  
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Proteomic research usually employs four types of mass analysers: ion trap IT/LTQ), time-of-flight (ToF), 
quadrupole and Fourier transform ion cyclotron (FTICR-MS) analysers (123). Each type of mass 
analyser has its own mass filtering method and some hybrid mass spectrometers combine two or more 
types to increase the analytical capabilities of the instrument (123).  
1.9.1.1 Hybrid mass spectrometers in proteomics 
Hybrid mass spectrometers combine the analytical power off two or more mass analysers into one 
instrument. These combinations increase the resolving power and mass accuracy of peptide spectral 
analysis in proteomic investigations (124). MS-based proteomic experiments typically analyse highly 
complex protein mixtures which presents a great analytical challenge. Proteins undergo proteolytic 
digestion to produce peptides which further add to the complexity of the experimental sample. Following 
proteolytic digestion peptides are separated by LC, converted into gaseous ions and analysed by 
tandem mass spectrometry. Due to the great abundance of peptides that are eluted into the mass 
spectrometer and the large order of magnitude difference of the ion signals, an instrument with high 
resolving power, duty cycle and sensitivity is required for proteomic experiments (125). One such 
instrument is the Orbitrap FusionTM TribridTM mass spectrometer (figure 1.6) used in this study. The 
Orbitrap Fusion is a hybrid mass spectrometer that combines a quadrupole, linear ion trap (LIT) and 
orbitrap mass analyser (discussed below) (126). The greatest attribute of the Orbitrap Fusion is the 
ability to perform high resolution multi-stage tandem experiments and simultaneously analyse ions in 
the orbitrap or LIT6. Sensitivity and ion selection are considerably enhanced by the quadrupole mass 
analyser which selects precursor ions of a particular m/z enabling parallel mass analysis7. Additionally 
the functionality of this hybrid mass spectrometer enables increased scan rate and several 
fragmentation techniques which when taken together with its other features provide high performance 
in proteomic investigations8. 
 
 










Figure 1.6: Schematic of the orbitrap fusion tribrid. The ‘T’ configuration of the instrument minimizes 
distance between the ion source and the mass analysers thereby reducing ion loss. This spatial 
configuration also provides sufficient space for ion fragmentation in the LIT which improves 
parallelized analysis. Modified with permission from Senko et al., 2013 (126).    
 
Quadrupole 
Quadrupole mass analysers consist of four cylindrical rods arranged parallel to each other with opposite 
pairs connected electrically (127). A direct current (DC) voltage and superimposed radio frequency (RF) 
voltage is applied to each pair of rods to create a symmetrical electric field (128). A positive DC voltage 
is placed on the first pair of rods while the second pair of rods carries a negative DC and the RF field is 
phase shifted by 180° (129). Ions entering the analyser are separated by the electric field which causes 
them to oscillate and attain one of two types of trajectory. At a particular DC and RF potential only ions 
of a particular m/z attain a stable trajectory along the axis of the quadrupole. These ions possess a 
“bounded oscillation” trajectory and ultimately pass on to the detector. Conversely ions of different m/z 
attain an unstable trajectory that is perpendicular to the path of flight. Ions with this unstable oscillatory 
pattern are discharged either on the rods or a pre-filter that may be fitted in front of the analyser. By 
altering the DC – RF voltage ratio (scan function) ions of different m/z pass onto the detector producing 
mass spectra of analyte ions. Quadrupoles are classified as scanning mass analysers and as such their 
scan function progresses in a linear manner such that obtaining spectra takes a long time. The limitation 
of the acquisition rate results in spectral bias. A positive aspect of this analyser is its ability to select 
and analyse an ion with a particular m/z. This is known as single ion monitoring (SIM) and the analyser 
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Liner Ion Trap 
Linear ion traps consist of a set of quadrupoles to which an RF voltage is applied producing an 
oscillating ion trajectory (128). In principle, linear ion traps have a similar operating principle to 
quadrupole mass analysers. A distinguishing feature of the linear trap is how ions are confined in 2D 
along the axis of a segmented quadrupole. The ions are confined radially and alternately travel between 
both ends of the quadrupole. Another feature of the ion trap is the incorporation of low pressure helium 
gas. The gas acts as a buffer which prevents repulsion between like charged ions and consequently 
increases mass accuracy and resolution (130). 
 
At the commencement of each trapping cycle the potential field is modulated to incorporate ions of a 
broad m/z spectrum into the trap (130). Following the trapping of ions in the analyser the field is further 
adjusted to confer a stable trajectory to all the ions present. Mass analysis is effected by a gradual 
increase in the amplitude of the RF trapping voltage which causes ions to have an unstable trajectory 
(125,127). This is known as resonant ejection and culminates in ions being ejected from the trap in 
order of increasing m/z and proceeding into the detector  (125,127). In this manner, a mass spectrum 
is generated by a trapping cycle and subsequent resonant ejection into the detector.   
 
Ion traps are renowned for sensitivity which relies on high efficiency of two aspects of the mass analyser. 
Sensitivity is dependent on efficient ion transmission from the mass analyser to the detector and 
maximal ion utilization (128). Efficient ion transmission may be attributed to the compact size of the 
analyser. Ion traps are designed in such a way that the trapping region is only a few centimetres from 
the detector (128). Also adding to the sensitivity of this instrument is the efficient utilization of ions 
produced by the ion source. This may be attributed to the ion trap-resonant ejection system of the mass 
analyser. Axial trapping of ions in the linear ion trap increases ion capacity, scan rate as well as 
detection and trapping efficiency. Consequently, these mass analysers are instrumental to proteomic 
studies as they can identify peptides in highly complex biological mixtures with remarkable sensitivity. 
Practicality convenience, low maintenance and the relatively cheap cost of this mass analyser are a 
few other factors that have made it popular in proteomic studies (131). 
 
Orbitrap 
An orbitrap mass analyser consists of a central (axial) spindle like electrode encapsulated by a coaxial 
outer barrel like electrode (128,129). This analyser does not rely on RF or magnetic fields like typical 
ion traps (133). Instead ions are orbitally trapped by an electrostatic force of attraction to the central 
spindle (133). Initial tangential force of ions generates a centrifugal force which balances this 
electrostatic field (130,131). The electrostatic fields produced by the axially symmetric electrodes of the 
orbitrap create a quadro-logarithmic electrostatic potential. In this electrostatic field trapped ions acquire 
a complex spiralling trajectory which consists of rotation around the central electrode and simultaneous 
harmonic oscillation (axial) along its length (130,133). The frequency of harmonic oscillation is 
independent of ion velocity and is inversely proportional to the square root of m/z (136). The axial 
oscillation of the ions creates an image current which is detected by the outer barrel electrode (137). 
Stellenbosch University  https://scholar.sun.ac.za
31 
 
The outer electrodes are split in half at z = 0 and each ion current is amplified differentially (138). The 
resulting signal is processed analogous to the FT-ICR to produce time domain image current transients 
(138). Mass spectrum are produced by Fourier transforming these transients (134).  
 
The orbitrap is a powerful mass analyser with renowned resolving power and high mass accuracy. It 
possesses a mass accuracy of 2-5 ppm, resolving power of 450 000, m/z range of 6000 and a dynamic 
range of 106 (137). In proteomic studies such high resolution allows the mass spectrometer to resolve 
near isobaric peptides in the same time window and helps prevent co-fragmentation. This is a 
prerequisite for accurate protein identification and quantification (139).  
1.9.2 MS based proteomic strategies for protein identification 
Analysis of the proteome utilises several technical methods that incorporate either of two strategies for 
the identification of proteins. The first strategy utilizes whole-intact proteins (top-down proteomics) while 
the second strategy relies on enzymatic or chemical proteolysis of proteins to derive peptides (bottom-
up proteomics or shotgun proteomics) for identification (121). A common feature of both top-down and 
bottom-up methods is the use of front end separation techniques that reduce sample complexity. 
Multiple stages of separation implement chromatographic techniques or polyacrylamide gel 
electrophoresis which increase overall sensitivity and reproducibility of results for the given experiment 
(109,120). 
1.9.2.1 Top-down proteomics 
The top down approach entails ionization of whole proteins, preliminary mass analysis, fragmentation 
and subsequent protein identification (121). Prior to sample infusion into the mass spectrometer, several 
fractionation strategies are used to reduce the great sample complexity. Some of these protein 
separation techniques include capillary electrophoresis, tube gel electrophoresis and LC. The majority 
of these separation strategies can be carried out offline which consequently increases data acquisition 
time and greatly reduces fractionation method-MS compatibility stringency (140). Sample separation of 
intact proteins poses a challenging task due to the co-elution of isotopic variants. This can however be 
circumvented by using mass analysers capable of high mass accuracy and resolution such as the FT 
ICR and orbitrap (112).   
 
Fragmentation methods commonly used in the top down approach include electron capture dissociation 
(ECD) and electron transfer dissociation (ETD) (112). These are the preferred fragmentation methods 
as they provide excellent sequence coverage and reliable characterization of labile PTMs (141). The 
top-down approach in combination with ETD/ECD fragmentation of intact proteoforms greatly simplifies 
protein quantification and increases resolution of protein isoforms due to greater sequence coverage 
(112). Furthermore reduced molecular complexity of fractioned and intact proteoforms minimizes 
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1.9.2.2 Bottom-up proteomics 
The bottom-up approach is the method of choice for high throughput analysis of highly complex 
samples. Using this approach, proteins undergo proteolysis to produce peptides prior to  mass 
spectrometry (112). The peptide fragment mass spectra produced by ion fragmentation are searched 
against protein databases by search engines such as Mascot or X!Tandem (111). Protein identities are 
assigned by comparing experimental fragment spectra to theoretical spectra generated by in silico 
proteolysis of a protein database. Peptides may be uniquely assigned to a single protein or several 
proteins (111). A protein identified by several unique peptide spectra improves the confidence of 
identification whereas a protein identified by few and redundant peptide spectra reduces the confidence 
of identification (142). Some advantages of the bottom-up method include better front end separation 
of peptides and increased sensitivity relative to the top-down method (121). Despite the effectiveness 
of the bottom-up approach in large scale analysis of different proteomes its greatest drawback lies in 
the increased sample complexity created by protein proteolysis. Peptides produced by proteolysis can 
sometimes be incorrectly assigned to proteins especially when they possess PTMs. Additionally, due 
to limitations in instrument dynamic range only the high abundant peptides generate a detectable ion 
signal while the ion signal of low abundant peptides is masked (121). 
1.9.3 Quantitative proteomics 
Quantitative proteomics is a high throughput method used to measure the relative or absolute 
abundance of proteins. The relative abundance of proteins between different experimental conditions 
such as the normal and disease state, or perturbed and control samples is an important feature of 
biomarker studies (139). Absolute protein quantification measures the exact amount of protein in a 
sample and is therefore better suited to targeted analysis of a specific protein (143). There are two 
approaches used to quantify proteins in proteomic studies, namely label free methods and isotope 
labelling methods (139).  
 
Label free quantification methods do not require the chemical modification of peptides as a prerequisite 
to protein quantification (144). The label free approach can follow either of two methods which are 
spectral counting and peptide peak intensity measurement (143). Spectral counting correlates the 
protein abundance to the amount of MS/MS spectra assigned to peptides or a specific protein (140,141). 
This is based on the principle that high abundant proteins produce more MS/MS spectra relative to low 
abundant proteins. Also the peptides of high abundant proteins undergo more sampling in fragment ion 
scans relative to low abundant peptides (143). In peptide peak intensity measurement protein 
abundance is correlated to spectral ion signal intensity (144). The peptide ion peaks from an LC-MS 
run are integrated and compared to other experimental values of the same ion species to determine the 
relative quantity (143). Implementation of label free quantification methods is becoming increasingly 
popular due to the following factors: low cost, less labour intensive and accommodation of a higher 
dynamic range (143).  
 
Isotope labelling quantification methods rely on the incorporation of a mass tag of known molecular 
weight either by a chemical or metabolic method. The incorporation of a differential mass tag does not 
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adversely alter the chemical properties of the protein or peptide (143). Downstream LC separation and 
MS analysis can therefore proceed unhindered. The principle of this quantification method is based on 
evaluation of the mass difference between equal amounts of peptides due to differential isotope 
labelling (145). Peptide samples are typically tagged with a combination of a heavy and light isotope/left 
unlabelled. The samples are pooled, analysed by MS and the ratio of the isotopic tag variants is used 
to determine protein relative abundances (145). In metabolic labelling a heavy isotope, typically 15N is 
introduced into proteins by culturing cells in media supplemented with a 15N  nitrogen source (144). 
Cells grown in 15N enriched media naturally integrate this heavy nitrogen isotope into protein during 
growth and division (139). Alternatively, labelling can be carried out by incorporation of heavy and light 
isoforms of either arginine or lysine into proteins via cell culture in a method called ‘stable isotope 
labelling by amino acids in cell culture’ (SILAC). Metabolic labelling methods are however only 
compatible with a limited number of biological studies. 
 
Chemical labelling methods offer a robust alternative making use of several methods such as isotope-
coded affinity tags (ICAT), isobaric tag for relative and absolute quantification (iTRAQ) and tandem 
mass tag (TMT) (144). The ICAT method is used to compare protein expression levels between two 
different samples. Using ICAT a chemical label is added to cysteine residues of peptides subsequent 
to protein trypsinization (145). This method reduces sample complexity since it only tracks peptides 
with cysteine residues which coincidentally occur with low frequency. ICAT labelling is not used in 
biomarker studies due to the bias in quantification introduced by tagging of low abundant cysteine 
residues and the fact that it can only analyse two samples/states at a given time. Biomarker discovery 
studies typically employ the isobaric tagging methods iTRAQ and TMT which can analyse up to 8 (10 
with TMT 10) samples in parallel (143). In iTRAQ and TMT variant isotopic tags are chemically attached 
to the primary amine groups on the peptides (144). Peptide fragmentation during MS analysis produces 
reporter ions. The relative intensity of these ions can then be used to determine the relative abundance 
of proteins (136,140).  
1.9.4 Secretome proteomics for biomarker discovery 
The term secretome refers to proteins that are released by a cell, tissue or organism. This also includes 
extracellular proteins and proteins that are shed from the cell membrane (146). Protein secretion is a 
cellular process carried out by either of two secretory pathways, the classical secretory pathway or the 
non-classical secretory pathway (147). The classical secretory pathway is well characterized and 
begins with synthesis of protein precursors in the rough ER. These protein precursors are transported 
to the Golgi apparatus and subsequently released into the microenvironment by fusion of secretory 
vesicles with the plasma membrane. Conversely, the non-classical secretory pathway is poorly 
characterized and it is thought that a relatively small proportion of proteins are secreted via this pathway 
(108,140) . Several mechanisms are responsible for protein secretion in the non-classical pathway and 
all lack the N-signal peptide sequence characteristic of proteins secreted by the classical pathway. In 
the first mechanism proteins are taken into endosomal compartments. Through the process of 
endosomal recycling in which the endosomes fuse with the plasma membrane, proteins are released 
into the extracellular space. The second mechanism is mediated by a ping-pong mechanism that 
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directly transports proteins into the extracellular space. A precondition for this mechanism is that the 
proteins are anchored to the membrane by dual acylation. Lastly, proteins may be secreted by 
exosomes via fusion of the plasma membrane and vesicle (147).        
 
Despite only 10-15% of the human genome encoding secreted proteins they play a vital physiological 
role in cell-cell communication, cell signalling and matrix remodelling (147). The secretome constitutes 
an important sub-class of the proteome as it is reflective of the dynamic inter-cellular crosstalk in an 
organism. The cancer secretome is therefore a viable source of biomarkers as it is involved in processes 
associated with tumour progression such as angiogenesis, metastasis, differentiation and invasion 
(148). Tumour progression is also dependent on the interaction between malignant cells and stromal 
cells cell in the tumour microenvironment. A host of signalling proteins such as cytokines, chemokines 
and growth factors mediate communication between the different cell types which favours progression 
of the malignant phenotype. Proteomic analysis of both the tumour and stromal cell secretome can thus 
provide a more comprehensive panel of biomarkers (147).  
 
MS based proteomic analysis of blood, conditioned media (CM) or tumour proximal fluid is the most 
widespread approach of mining the cancer secretome for biomarkers (149). Human blood by far 
presents the largest repository of potential biomarkers. However, LC-MS/MS analysis of blood has 
proven challenging due to the large diversity of proteins with a dynamic range of 9-10 orders of 
magnitude. High abundant proteins such as albumin, immunoglobulin and transferrin tend to have a 
masking effect on the low abundant secreted proteins. Separation methods to reduce blood complexity 
such as immunoaffinity chromatography and Protein G resins have been implemented to remove high 
abundant protein species. These protein depletion strategies however lower the accuracy of the 
investigation due to non-specific binding and proteins of interest forming complexes with the filtered 
high abundant proteins (149).  
 
An alternative source of secreted biomarkers lies in the CM of cancer cell lines. Cancer cell lines secrete 
and shed proteins into the CM which is collected and subsequently analysed. CM is considerably less 
complex compared to blood and tumour proximal fluid such that low abundant proteins can be easily 
identified. Furthermore, cancer cell lines are grown under standardized conditions which increases 
reproducibility of results. Different cell lines are representative of varied tumour histotypes and stage 
thus increasing the scope of the study and accounting for the heterogeneity of cancer. The drawback 
of CM analysis however, lies in the fact that tissue culture does not completely mimic the different 
factors and physiological interactions that account for the complexity of cancer. Also, altered protein 
expression in cell lines can be attributed to stressful growth conditions encountered in tissue culture 
(147). 
 
Tumour interstitial fluid is yet another viable source of secreted protein biomarkers. Tumour proximal 
fluid is a biological fluid that surrounds both stromal and tumour cells. It is a rich source of biomarkers 
as tumour cells secrete signalling molecules involved in metastasis and progression directly into this 
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fluid. An advantage of this biomarker source is that it is a direct source of secreted proteins from tumour 
cells in vivo but with relatively less complexity in comparison to blood (150). The main drawback of 
tumour proximal fluid lie in its extraction which can result in contamination by serum proteins (147). 
Tumour progression is a multi-step process that incorporates a host of signalling factors and different 
cell types. It has become evident that tumour cells recruit proximal stromal cells in their 
microenvironment that promote metastasis and invasion of distant organs. Therefore, analysis of the 
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1.10 Aims and objectives  
This study aim to identify novel biomarkers which can be used to distinguish BPH from PCa by 
comparative proteomic analysis of the secretome and proteome of prostate cancer cells. This study 
used a tissue culture based model to generate profiles for the secretome and proteome of prostate cell 
lines. For the investigation of the secretome, cells were grown in serum free media which was 
concentrated and analysed by LC-MS/MS. For the proteome study, cells were grown, collected and 
analysed by LC-MS/MS. The proteins that were identified by MS were compared between the four cell 
lines and the differentially expressed proteins in BPH-1 cell line were further investigated as potential 
biomarkers. The specific objectives of this study were as follows: 
 
1. To optimize the growth conditions of the prostate cell lines (LNCaP, PC3, PNT2 and 
BPH-1) in order to reduce cell death and maximize the levels of secreted proteins. 
 
2. To optimize purification methods of secreted proteins in the conditioned media. 
 
3. To investigate the secretome and proteome of four prostate cell lines (BPH-1, LNCaP, 
PC3 and PNT2) using mass spectrometry based proteomics. 
 



























LNCaP, PC-3 and PNT2 cells were purchased from the European Collection of Authenticated Cell 
Cultures (ECACC). BPH-1 cells were a generous gift from Simon W Hayward (Vanderbilt University of 
Medical Center, Nashville, USA). Ham’s F12K medium, RPMI-1640 medium, acetone (HPLC grade) 
and 3.5 kDa dialysis membrane were all purchased from Sigma-Aldrich (St. Louis, MO, USA). Chinese 
hamster ovary medium (CDCHO), L-glutamine, penicillin-streptomycin, fetal calf serum (FCS) and 
trypsin-EDTA were obtained from Gibco-BRL (Gaithersburg, MD, USA). Bicinchoninic acid (BCA) 
protein determination kits and lactate dehydrogenase cell viability assays were purchased from Pierce 
(Rockford, IL, USA) and Roche Diagnostics (Mannheim Germany), respectively. Trypan blue stain 
(0.4%) and cell count plates were purchased from Invitrogen (Eugene, USA). Corning® CellBIND® T-
175 flasks were purchased from Corning® Life Sciences (NY, USA) and ammonium sulphate was 
purchased from Protea Chemicals (Western Cape, South Africa). All other chemicals were of the 
highest analytical grade and purchased from scientific supply houses. All protocols were carried out 
according to the manufacturer’s instructions unless otherwise stated. 
2.2 Prostate cell line tissue culture 
2.2.1 Cell culture general growth conditions 
BPH-1 and PNT2 cells were grown in RPMI-1640 media supplemented with 10% fetal calf serum 1.5 g 
NaHCO3/L (pH 7) and 1% penicillin-streptomycin. PC-3 cells were grown in Ham’s F12K media 
supplemented with 10% FCS, 1.5 g NaHCO3/L (pH 7) and 1% penicillin-streptomycin. LNCaP cells 
were grown in RPMI-1640 media supplemented with 10% fetal calf serum (FCS), 1.5 g NaHCO3/L (pH 
7), 2.5 g D-(+)-Glucose, 1% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1% sodium 
pyruvate and 1% penicillin-streptomycin. All cell lines were grown in a humidified incubator at 37°C and 
5% CO2. Cell count and viability were determined using trypan blue and a Countess® Automated cell 
counter (Invitrogen).  
2.2.2 Cell culture growth conditions for analysis of the proteome 
All cell lines were maintained as described in section 2.2.1 above. On the third passage all cell lines 
were plated in 75 cm2 tissue culture flasks at a density of 5x104 cells/mL(10mL) and were grown to 80% 
confluency. Once the cells had reached the desired confluence the media was aspirated from the 
culture flasks and the cells were gently washed with 20 mL of phosphate buffered saline (PBS) (pH 
7.4). The cells were detached from the flasks using 4 mL pre-warmed trypsin. The detached cells were 
transferred into a conical tubes containing 10 mL of conditioned media and centrifuged at 600 x g for 5 
minutes. Following centrifugation the conditioned media was aspirated, the cell pellet was re-suspended 
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in 10 mL PBS and again centrifuged at 600 x g for 5 minutes. The cells were then re-suspended in 1 
mL of PBS and centrifuged at 600 x g for 5 minutes. This step was repeated once more in order to 
remove serum proteins from the FCS used to supplement conditioned media. The PBS was 
subsequently aspirated, the cells were weighed and the mass was adjusted to 50 mg for each biological 
repeat by pipetting off excess cells. The samples were stored at -80˚C till until use. Three independent 
biological experiments were performed for each cell line. 
2.2.3 Cell culture growth conditions for analysis of the cell secretome 
All cell lines were maintained as described in section 2.2.1 above. On the third passage BPH-1, PNT2 
and PC-3 cells were plated into T175 flasks at varying densities in 30 mL of their respective CM. BPH-
1 cells were seeded at 2, 5 and 8 million cells per flask; PNT2 cells were seeded at 4, 6 and 8 million 
cells per flask; PC-3 cells were seeded at 5, 8 and 11 million cells per flask; and LNCaP cells were 
seeded at 11, 16.5 and 22 million cells per flask. The cells were then incubated for 48 hours, with the 
exception of the LNCaP cells which were incubated for 72 hours. Following this incubation period, the 
conditioned media was aspirated and cells were gently washed twice with 20 mL of PBS. Next, the cells 
were incubated in 30 mL of CDCHO supplemented with L-glutamine (8 mmol/L) for 48 hours. After 
incubation in CDCHO, the conditioned media was collected and centrifuged at 600 x g for 5 minutes to 
remove cellular debris. Aliquots of the conditioned media were then collected for the measurement of 
total protein and LDH while the remainder was stored at -80˚C until further use. 
2.3 Measurement of total protein and LDH 
Total protein in the conditioned media was measured by the Bradford assay. Twenty microliters of each 
secretome sample was thawed and added to a 96 well transparent microplate (Greiner Bio-One 
International) in triplicate, together with a range of bovine serum albumin (BSA) standards which were 
prepared in deionized water (table 2.1.). Samples were incubated at room temperature for 30 minutes 
following the addition of 200 µL of Bradford reagent into each well. Absorbance at 540 nm was 
subsequently measured (Biotek Powerwave 340 Plate Reader). The average absorbance 
measurement for the blank (CDCHO) replicates was subtracted from the measurements of all other 
individual standard and unknown sample replicates. The standard curve was then generated by plotting 
the blank-corrected measurement for each BSA standard versus concentration. The standard curve 












Table 2.1: Preparation of protein standards for Bradford protein assay. 
Dilution Volume of deionized 
water (μL) 
Volume and source of 
BSA (μL) 
Final BSA concentration 
(μg/mL) 
A 0 300 of stock (2mg/mL) 2000 
B 125 375 of stock (2mg/mL) 1500 
C 325 325 of stock (2mg/mL) 1000 
D 175 175 of B dilution 750 
E 325 325 of C dilution 500 
F 325 325 of E dilution 250 
G 325 325 of F dilution 125 
H 400 100 of G dilution 0 
I 400 0 0 = Blank 
 
LDH concentration in the conditioned media was measured by an LDH assay kit (Roche Diagnostics) 
that reduces NAD to NADH. This reaction was detected by a colorimetric assay that produces a 
characteristic red formazan product which was measured spectrophotometrically at a wavelength of 
492 nm.  
One hundred microliters of each secretome sample was thawed and added to a 96 well transparent 
microplate (Greiner Bio-One International) in triplicate together with a range of LDH (table 2.2) 
standards prepared in CDCHO medium (table 2.2). The LDH stock solution was prepared by adding 2 
µL of LDH stock (ScienCell) to 498 µL of PBS (final concentration 1000 mU/mL). Samples were 
incubated at room temperature in the dark for 30 minutes following the addition of 100 µL of working 
reagent. Absorbance at 492 nm was subsequently measured (Biotek Powerwave 340 Plate Reader). 
The average absorbance measurement of the blank (CDCHO medium) replicates was subtracted from 
the measurements of all other individual standard and unknown sample replicates. The standard curve 
was then generated by plotting the blank-corrected measurement for each LDH standard versus 
concentration. The standard curve was subsequently used to determine the LDH concentration for each 
unknown sample. 
Table 2.2: Preparation of LDH standards for LDH cell viability assay. 
Dilution Volume of CDCHO 
added (μL) 
Volume and source of 
LDH (μL) 
Final LDH concentration 
(mU/mL) 
1 450 450 of stock 
(1000mU/mL) 
500 
2 450 450 (of dilution 1) 250 
3 450 450 (of dilution 2) 125 
4 450 450 (of dilution 3) 62,5 
5 450 450 (of dilution 4) 31,8 
6 450 450 (of dilution 5) 15,6 
7 450 450 (of dilution 6) 7,8 
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2.4 Optimization of protein precipitation from conditioned media 
Samples were prepared by pooling three 25 mL secretome samples from the BPH cell line and stirring 
for 15 minutes to achieve homogeneity. The pooled samples were then aliquoted equally into three 
conical tubes. Each conical tube containing 25 mL of the homogenous secretome sample underwent 
one of three protein precipitation techniques (described below). Protein concentration was determined 
using the Pierce BCA method subsequent to protein precipitation to evaluate the effectiveness of each 
technique. The experiment was repeated using pooled PNT2 secretome samples. 
2.4.1 Acetone precipitation 
Acetone was cooled overnight to -20˚C while the protein samples where thawed at 4°C. Four volumes 
(100 mL) of cooled acetone was subsequently added to a precooled conical flask followed by one 
volume of the secretome sample (25 mL). The acetone-sample mixture was then stirred for 5 minutes 
and incubated overnight at -20°C. Next, the mixture was centrifuged at 15000 x g for 10 minutes. The 
supernatant was discarded and the protein pellet was air dried. Following this, the protein pellet was re-
suspended in 5 mL of deionized water and lyophilized overnight by a speedy-vac (LabConco Centrivap). 
The samples were re-suspended in 2 mL of deionized water and the protein concentration was 
determined using the BCA assay. All samples were stored at -80˚C after the protein concentration 
determination for later use. 
2.4.2 Ammonium sulphate precipitation 
A 25 mL of a secretome aliquot was poured into a 50 mL centrifuge tube and a pre-determined amount 
of ammonium sulphate (13.32 g) was added in order to obtain 80% saturation. The mixture was then 
incubated overnight at 4°C. Next, the protein-salt mixture was centrifuged at 10000 x g for 20 minutes. 
The resulting supernatant was discarded and the protein pellet was re-suspended in 5 mL deionized 
water. The re-suspended protein was dialyzed for 24 hours using a 3.5 kDa cut-off dialysis tubing at 
4°C in 5 L of deionized water. The deionized water was changed twice after 4 hour intervals. Following 
dialysis, the sample was lyophilized overnight by a speedy-vac (LabConco Centrivap) to concentrate 
the protein and then re-suspended in 1 mL of deionized water. The protein concentration was 
subsequently determined by the BCA assay. Samples were then stored at -80˚C until required for further 
use. 
2.4.3 Acetone-Phosphotungstic Acid (PTA) precipitation 
Acetone was cooled overnight to -20˚C while the protein samples where thawed at 4°C. Four volumes 
(100 mL) of cooled acetone were subsequently added to a precooled conical flask followed by one 
volume of the secretome sample (25 mL). PTA was then added to a final concentration of 1.2% in the 
acetone-sample mixture. The acetone-sample mixture was stirred for 5 minutes and left to stand 
overnight at -20°C. Next, the mixture was centrifuged at 15000 x g for 10 minutes. The supernatant was 
discarded and the protein pellet was air dried. Following this, the protein pellet was re-suspended in 5 
mL of deionized water and lyophilized overnight by a speedy-vac (LabConco Centrivap). The samples 
were re-suspended in 2 mL of deionized water and the protein concentration was determined by the 
BCA assay. Samples were then stored at -80˚C until required for further use. 
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2.4.4 BCA protein determination  
Protein concentration following precipitation was measured using the Pierce BCA assay (Thermo 
Scientifc). The BCA assay was preferred to the Bradford method due to the incompatibility of the latter 
method with residual acetone present in the precipitated samples. Twenty five microliters of each 
secretome sample was thawed and added to a 96 well transparent microplate (Greiner Bio-One 
International) in triplicate together with a range BSA standards prepared in deionized water (table 2.1.). 
Samples were incubated at room temperature for 30 minutes at 37°C following the addition of 200 µL 
of working reagent into each well. The absorbance was subsequently measured at 562 nm (Biotek 
Powerwave 340 Plate Reader). The average absorbance measurement of the blank (deionized water) 
replicates was subtracted from the measurements of all other individual standard and unknown sample 
replicates. The standard curve was then generated by plotting the blank-corrected measurement for 
each BSA standard versus concentration. The standard curve was subsequently used to determine the 
protein concentration for each unknown sample 
 
Table 2.3: Preparation of protein standards for BCA protein assay. 
Dilution Volume of deionized 
water (μL) 
Volume and source of 
BSA (μL) 
Final BSA concentration 
(μg/mL) 
A 0 300 of stock (2mg/mL) 2000 
B 125 375 of stock (2mg/mL) 1500 
C 325 325 of stock (2mg/mL) 1000 
D 175 175 of B dilution 750 
E 325 325 of C dilution 500 
F 325 325 of E dilution 250 
G 325 325 of F dilution 125 
H 400 100 of G dilution 0 
I 400 0 0 = Blank 
 
2.5 Preparation of cell pellets for Mass Spectrometry 
Cells were thawed in 100 µL of extraction buffer containing 100 mM NaCl, 2 mM EDTA, 6 M guanidine-
HCl, 1% OGP and 5 mM TCEP in 100 mM triethylammonium bicarbonate (TEAB, pH8). The cell-
extraction buffer suspensions were sonicated and centrifuged at 12000 x g for 5 minutes and the 
supernatant collected. The pellet was re-suspended in 50 µL of extraction buffer and subjected to a 
second round of extraction. The resulting supernatants were pooled with the supernatants generated 
in the initial round of extraction. Proteins were subsequently precipitated with ice cold acetone in a 1:5 
sample to acetone ratio. Proteins were allowed precipitate overnight before pelleting by centrifugation 
at 12 000 x g for 10 minutes.  The resulting supernatant was discarded and the pellet air dried before 
being re-suspended in 100 µL of 100 mM TEAB containing 4 M guanidine-HCl and 1% octylgluco-
mano-pyranoside. The disulphide bonds in the protein samples were then reduced uby adding 10 µL of 
50 mM TCEP (final concentration of 5 mM) in 100 mM TEAB for 30 minutes at room temperature. 
Following this the reduced cysteine residues were subsequently modified using 5 µL of 200 mM methyl 
methanethiosulfonate (MMTS) (final concentration of 20 mM) in 100 mM TEAB buffer for 30 minutes. 
The samples were then diluted to 98 µL with 100 mM TEAB. Next, proteins were digested by adding 10 
µL trypsin (Pierce) solution (1 µg/µL) and incubating for 6 hours at room temperature followed by a 
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further 16 hours at 37 °C. Samples were subsequently dried and re-suspended in 100 µL of 2% 
acetonitrile containing 0.1% formic acid and subsequently de-salted using C18 stage tips. Three 
independent biological experiments were performed for each cell line. Individual samples were 
analysed in triplicate using LC-MS. 
2.6 LC-MS analysis of the cell proteome 
Peptides were separated by liquid chromatography using a Thermo Scientific Ultimate 3000 RSLC 
equipped with a C18 trap column (300 µm x 5 mm (Thermo Scientific)) and an in house manufactured 
analytically column (75 µm x 40 cm). The mobile phases consisted of solvent A (2% acetonitrile:water; 
0.1% formic acid) and solvent B (100% acetonitrile:water). Flow rate was set to 350 nL/minute and the 
gradient as follows: 2% A for 5 minutes; 2 - 4% B from 5-10 minutes, 4 - 10% from 10-20 minutes, 10 - 
40% from 20-95 minutes using Chromeleon non-linear gradient 7, 40 - 80% B and from 95-100 minutes. 
Thereafter the column was washed for 10 minutes with 80% B followed by equilibration. 
Chromatography was performed at 50°C and the outflow delivered to the mass spectrometer through 
a stainless steel nano-bore emitter. Eluted peptides were analysed by an Orbitrap Fusion Tribrid mass 
spectrometer (Thermo Scientific) equipped with a Nanospray Flex ionization source. Data was collected 
in positive mode with spray voltage set to 2 kV and ion transfer capillary set to 275°C. Spectra were 
internally calibrated using polysiloxane ions at m/z = 445.12003 and 371.10024. MS1 scans were 
performed using the orbitrap detector set at 12 000 resolution over the scan range 350-1650 with AGC 
target at 3 E5 and maximum injection time of 40ms. Data was acquired in profile mode. MS2 acquisitions 
were performed using monoisotopic precursor selection for ion with charges +2- +6 with error tolerance 
set to +/- 10ppm. The raw files generated by the MS analysis were imported into Proteome Discoverer 
v1.4 (Thermo Scientific) and processed using the Mascot and SequestHT algorithms. Peptide validation 
was set to search against a false decoy rate (FDR) of 1%. Additional analyses were performed using 
the X!Tandem Sledgehammer algorithm. The files generated by data analysis of the spectra were 


















3.1 Optimization of secretome samples 
The total protein and LDH concentration in the conditioned chemically defined serum free media 
obtained from the BPH-1, PNT2, LNCaP and PC3 cell lines was measured. The ratio of LDH to total 
protein concentration was determined for each seeding density for all cell lines in order to determine 
the optimal seeding density. The optimal seeding density was considered to be that density that had 
the highest amount of secreted proteins, but lowest amount of intracellular proteins as measured by the 
LDH assay. Intracellular proteins have a masking effect on relatively low abundant secreted proteins, 
therefore optimization maximises the amount of secreted proteins and increases the depth of secretome 
coverage. 
The protein concertation was determined using the Bradford protein determination method as described 
in section 2.3. Unsurprisingly, the total protein concentration tended to increase with the seeding 
density, however, this trend was not significant in all cases. Statistically significant differences included 
a 2.5-fold increase in protein concentration between the lowest seeding density and 5×106 cells and a 
3.0-fold increase between the lowest seeding density and 8×106 cells for the BPH-1 cell line. A 2.0-fold 
increase in protein concentration was observed between the lowest and highest seeding density in the 
PC3 cell lines, while in the LNCaP cell line a 2.10-fold increase was observed between the lowest and 
highest seeding density. No statistically significant differences were observed in the PNT2 cell line. The 
total protein concentrations for the cell lines (figure 3.1) are listed below in order of increasing seeding 
density: BPH-1- 13.93 µg/mL, 34.27 µg/mL and 41.88 µg/mL; PNT2- 19.08 µg/mL, 24.97 µg/mL and 
31.12 µg/mL; LNCaP- 15.10 µg/mL, 22.89 µg/mL and 32.17 µg/mL; PC3- 11.52 µg/mL, 18.72 µg/mL 




























Figure 3.1: Total protein content in the serum free conditioned media from (A) BPH-1, (B) PNT2, (C) 
PC3 and (D) LNCaP cell lines. Results are shown as means ± SEM of three independent experiments 
each performed in triplicate. One-way analysis of variance (ANOVA) with Tukey’s post-test were used 
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The LDH concentration was measured in the conditioned chemically defined serum free media of 
prostate cell lines using a commercially purchased LDH kit as described in section 2.3. Similar to the 
protein concentration, the LDH levels tended to increase with increased seeding densities (figure 3.2), 
though this trend was again not significant in all cases. In BPH-1 all the observed trends were 
statistically significant. The fold increase in LDH concentration were 2.4 (5×106 cells) and 3.0 (8×106 
cells) with respect to the lowest seeding density. The trends in PNT2 LDH concentrations were as 
follows: a 2.6-fold increase in LDH concentration between the lowest seeding density and 6×106 cells 
(P< 0.05) and a 4.0-fold increase between the lowest seeding density and 8×106 cells (P< 0.001). PC3 
showed a 1.6-fold increase in LDH concentration between 5×106 cells and 11×106 cells (P< 0.001) and 
a 1.3-fold increase between 8×106 cells and 11×106 cells (P< 0.05). The trends observed in LNCaP 
were not statistically significant. The LDH concentrations for the cell lines are listed below in order of 
increasing seeding density: BPH-1- 381.80 mU/mL, 917.99 mU/mL, 1137.57 mU/mL; PNT2- 132.34 
mU/mL, 345.29 mU/mL and 531.22 mU/mL; LNCaP- 266.83 mU/mL, 445.39 mU/mL and 802.78 








































Figure 3.2: LDH concentrations in the serum free media of four prostate cell lines. Concentration of 
LDH (A) BPH-1 (B) PNT2 (C) PC3 and (D) LNCaP at different seeding densities. Results (A), (B), (C) 
and (D) are shown as means ± SEM of three independent experiments performed in triplicate. One-
way analysis of variance (ANOVA) with Tukey’s post-test were used for group comparisons. *P < 0.05; 
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The most informative way to assess the seeding densities may be to compare the ratio of LDH to protein 
concentration (figure 3.3). The smallest LDH/protein ratio would indicate the optimal samples. The ratio 
of LDH/protein for the cell lines are listed below in order of increasing seeding density: BPH-1- 27.44 
mU/µg, 29.07 mU/µg and 27.57 mU/µg; PNT2- 7.54 mU/µg, 15.29 mU/µg and 17.21 mU/µg; LNCaP- 
17.67 mU/µg, 19.23 mU/µg and 23.81mU/µg; PC3- 19.43 mU/µg, 17.63 mU/µg and 17.47mU/µg. No 
statistically significant differences were observed in the LDH/Protein ratios with the exception of PNT2 
(4×106 cells and 8×106 cells). As a result of the observation that the LDH/Protein ratios were similar 
across the seeding densities in most cases it was decided to instead consider the LDH values as LDH 
is a reliable indicator of the amount of intracellular proteins in each sample and intracellular proteins 
are known to have a masking effect on low abundant secreted proteins during LC-MS/MS. For this 
reason the lowest seeding density for each cell line was selected as the optimal seeding density (2x106, 








































Figure 3.3: Ratio of LDH to total protein concentration of conditioned media from four prostate cell lines 
at different seeding densities. Ratios were as follows: (A) BPH-1 (B) PNT2 (C) PC3 and (D) LNCaP at 
different seeding densities.  Results (A), (B), (C) and (D) are shown as means ± SEM of three 
independent experiments performed in triplicate. One-way analysis of variance (ANOVA) with Tukey’s 
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3.2 Optimization of protein precipitation methods 
Protein precipitation is commonly employed as an initial protein purification step when investigating 
secreted proteins in conditioned media. It was therefore important to evaluate different protein 
precipitation techniques to determine the method of choice for maximizing protein recovery from 
conditioned media. The ammonium sulphate, methanol-chloroform, acetone and acetone-
phosphotungstic acid protein precipitation methods were compared in this study. These methods exert 
different modes of action that facilitate varying amounts of protein precipitation for downstream LC-
MS/MS. 
 
Methanol-chloroform precipitation extracts proteins from solution by exploiting the principle of phase 
separation of a polar (methanol) and non-polar (chloroform) solvent. The addition of water to this solvent 
mixture induces phase separation into a hydrophobic and hydrophilic layer. Precipitated proteins collect 
at the interface of the two solvents known as the interphase. Ammonium sulphate precipitation removes 
the hydration layer of water molecules associated with charged side chains and polar groups on the 
protein surface. The hydration layer is crucial for maintaining solubility and correct conformation of 
proteins in solution. The addition of salt increases the surface tension of water increasing the interaction 
of hydrophobic groups on the protein and water. This results in hydrophobic groups associating leading 
to precipitation (151). Acetone precipitation relies on a similar principle of hydrophobic segregation to 
achieve protein precipitation. The addition of increasing amounts of acetone reduces the dielectric 
constant of the solvent thereby reducing its polarity. The reduction in solvent polarity coincides with a 
reduction in solubility of the protein which effects precipitation. In addition to disruption of the solvation 
layer, acetone also partially denatures the protein which exposes more hydrophobic groups resulting in 
increased protein aggregation. Acetone can also be used in combination with phosphotungstic acid 
(PTA) for protein precipitation. PTA is a heteropoly acid (H3PW12O40) used as an alkaloidal protein 
precipitating agent. It lowers the pH of a medium resulting in the majority of proteins carrying a net 
positive charge. Protein cations in the medium form complexes with negatively charged acid molecules 
to form a protein-tungstate flocculent precipitate. 
 
Protein precipitation experiments were carried out on pooled secretome samples from the BPH-1 and 
PNT2 cell lines (described in section 2.4). The methanol-chloroform technique failed to recover 
detectable levels of protein from the conditioned media. Acetone based techniques delivered greater 
protein recovery in comparison to the ammonium sulphate and acetone-PTA precipitation methods 
(figure 3.4). Differences between the amounts of protein recovered by each precipitation method for 
both BPH-1 and PNT2 were statistically significant. In the conditioned media of BPH-1 there was 28-
fold increase in the amount of protein recovered by acetone relative to ammonium sulphate (P < 0.001), 
and a 19-fold increase in the protein recovered by acetone-PTA relative to ammonium sulphate (P < 
0.001). This trend in protein recovery was similar when the experiment was repeated on the conditioned 
media of PNT2. There was a 16-fold increase in the amount of protein recovered by acetone relative to 
ammonium sulphate (P < 0.001), and a 13-fold increase in the amount of protein recovered by acetone-
PTA relative to ammonium sulphate (P < 0.001). The amount of protein recovered from the conditioned 
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media of BPH-1 cell line was 22.5 mg, 15 mg and 0.78 mg for acetone, acetone-PTA and ammonium 
sulphate precipitation method, respectively. The amount of protein recovered from the conditioned 
media of PNT2 cell line was 18.23 mg, 15 mg and 1.13 mg for acetone, acetone-PTA and ammonium 























Figure 3.4: Total protein (mg) precipitated from conditioned media of the (A) BPH-1 and (B) PNT2 cell 
lines. Results are shown as means ± SD of a single experiments measured triplicate. One-way analysis 
of variance (ANOVA) with Tukey’s post-test were used for group comparisons. *P < 0.05; **P < 0.01; 
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3.3 Characterization of the proteome 
The proteome of four prostate cell lines was analysed using LC-MS/MS. Three independent biological 
replicates were prepared for each cell line and each replicate was analysed in triplicate. X!Tandem and 
Sequest search engines were used to identify individual peptides. This data was subsequently imported 
into Scaffold (version Scaffold_4.4.8, Proteome Software Inc., Portland, OR) which was used for 
subsequent protein assignment. Positive peptide identification was accepted at a cut-off threshold of 
90% probability. Peptide spectrum matches were generated in X!Tandem and subsequently validated 
and filtered by the Peptide Prophet algorithm. Peptide spectrum matches generated by Sequest were 
subsequently processed by Peptide Prophet and Protein Prophet. The peptides identified by both 
search engines were consolidated in Scaffold and used for protein identification. Positive protein 
identifications were accepted at an FDR of less than 1.0% and if they contained at least 2 peptides. The 
FDR was determined by searching the peptide assignments against a concatenated target decoy 
database using the same search parameters and Scaffold cut-offs. The total number of proteins 
assigned per cell line were as follows: 2079 in BPH-1, 2081 in LNCaP, 1853 in PC3 and 2137 proteins 
in the PNT2 cell line. A total of 655 proteins shown in figure 3.6 (A) were common to all cell lines and 
the number of unique proteins identified in each cell line were as follows: BPH-1; 473 (23%), LNCaP; 

































Figure 3.5: Venn diagram showing the overlap of all proteins identified in the BPH-1, LNCaP, PC3 and 
PNT2 cell lines. Proteins were positively identified with an FDR of 1.0% and a minimum of two peptides.  
 
3.3.1 Subcellular localization of identified proteins 
The proteins identified in all cell lines were cross referenced with the Gene Ontology database. The 
cellular localizations that the proteins were designated included extracellular, intracellular, endoplasmic 
reticulum, Golgi apparatus, nucleus, endosome, and membrane (figure 3.6). Proteins that did not 
possess a Gene Ontology classification or did not belong to any of the given cellular localizations were 
listed as being unclassified. Interestingly, the number of unclassified proteins accounted for a large 
percentage of the identified proteins: BPH-1; 44%, PC3; 12%, PNT2; 42%, LNCaP; 35%. Intracellular 
and nuclear proteins were among the top three annotated proteins ranging from 14-18% for the nucleus 
and 19-26% for intracellular proteins. Extracellular proteins accounted for 7% of annotated proteins in 
BPH-1, PNT2 and LNCaP, and 19% in PC3. The distribution of membrane proteins was as follows: 
BPH-1; 9%, PC3; 15%, PNT2; 10%, LNCaP; 11%. The endoplasmic reticulum, Golgi apparatus, 
mitochondria and endosome accounted for a relatively small percentage of annotated proteins ranging 
from 1-5% across the cell lines. It should also be noted that there may be some redundancy in the 
classification of proteins by subcellular location as proteins can be listed under more than one sub 













































Figure 3.6: The subcellular cellular distribution of proteins positively identified in the BPH-1, LNCaP, 
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Extracellular and membrane bound proteins are the most likely proteins to be detected in the secretome 
and were thus analysed further to identify candidate biomarkers for BPH (figure 3.7). Analysis of this 
sub proteome identified 26 proteins common to all cell lines. The number of unique proteins were as 
follows: BPH-1; 110 (27%), LNCaP; 86 (33%), PC3; 180 (70%), PNT2; 25 (8%). A literature review of 
the 110 proteins that were unique to BPH-1 identified mesencephalic astrocyte-derived neurotrophic 
factor (MANF) as a candidate biomarker. All other proteins were excluded as potential biomarkers for 
BPH as they had previously been associated with prostate cancer and/or other cancer types.. Refer to 
table G in the appendix for a comprehensive list of the positively identified proteins unique to BPH-1 in 



















Figure 3.7: Venn diagram showing the overlap of extracellular and membrane bound proteins identified 
in the BPH-1, LNCaP, PC3 and PNT2 cell lines. Proteins were positively identified with an FDR of 1.0% 




























3.3.2 Pathway analysis 
Comparative analysis of the cell secretome was the first approach that was used to identify biomarkers 
in this study and only yielded one candidate tumour marker, namely MANF. The second approach 
focussed on identifying pathways that were altered in the BPH disease state. Pathway analysis was 
carried out using the Ingenuity Pathway Analysis (IPA) software package http://www.ingenuity.com).  
IPA is a database that serves a repository for biological, functional annotations and pathway models for 
genes, proteins, cell lines and tissue. Using this software, the experimental data set was cross 
referenced with the Ingenuity Knowledge base and mapped to the most relevant canonical pathways. 
A comparative analysis was used to evaluate the relative differences in pathways between two disease 
states of the prostate with normal prostate cells represented by the PNT2 cell line acting as a reference 
for fold changes in the other prostate cell lines. Fold changes were first determined in Scaffold prior to 
IPA analysis and only fold changes with a p-value of less than 0.05 were included in the subsequent 
IPA analysis. Protein identities from the experimental datasets were mapped against the IPA database 
and the most highly matched canonical pathways were displayed in order of statistical significance. The 
statistical significance is expressed as –log(p) which is calculated by the Fisher’s exact test right-tailed. 
Therefore, the greater the –log(p) value, the more statistically significant the matched canonical 
pathway.  
The two most variant canonical pathways in BPH are shown in figure 3.8. The overlap between dataset 
proteins and these canonical pathways where as follows: pyrimidine ribonucleotides de novo synthesis, 
21.1%; antiproliferative role of TOB in T cell signalling, 16.7%. Refer to tables A-E in the appendix for 
log ratios and p-values for proteins mapped to the 5 canonical pathways shown in figure 3.8. 





Figure 3.8: Canonical pathways from the IPA database that showed the greatest difference between 
BPH-1, PC3 and LNCaP datasets. The significance of this overlap was measured as a ratio of the 
number of molecules from the dataset that map to the pathway divided by the total number of proteins 
associated with that particular pathway. Fisher’s exact test was used to calculate the statistical 
significance of proteins from the datastet that were matched to the canonical. A p-value of 0.01 was 
considered significant. Threshold p < 0.01 is shown as yellow line. Bars that are above the line indicate 
significant enrichment of a pathway. 
3.3.3 Disease and function pathway analysis  
Following the analysis of canonical pathways, disease and functions associated with BPH were 
analysed by IPA as described in section 3.3.2. A Fisher’s exact test, set at a threshold of 0.01, was then 
carried out to determine the probability of overlap between the input gene set and the genes present in 
each annotated disease/function. Vitamin and mineral metabolism, and cell signalling are cell functions 
that showed significant association with BPH-1 exclusively (figure 3.9). The HSPA5 gene was mapped 
to both functions. HSPA5 encodes Heat shock 70-kDa protein 5 which is involved in calcium 
homeostasis and acts as signal receptor localized in the plasma membrane (152,153). 
 
 
BPH-1 LNCaP PC3 






Figure 3.9: Comparison of disease and functions from the BPH-1, PNT2 and LNCaP dataset. The 
significance of this overlap was measured as a ratio of the number of molecules from the dataset that 
map to the pathway divided by the total number of proteins associated with that particular pathway. 
Fisher’s exact test was used to calculate the statistical significance of proteins from the datastet that 
were matched to the canonical pathwyas. A p-value of 0.01 was considered significant.  
3.3.4 Network analysis  
Canonical pathway analysis together with disease and function analysis revealed the pathways that 
were altered in the BPH disease state. In order to visualize the interaction of proteins in the BPH-1 
dataset and gain an understanding of how they contribute to the pathobiology of BPH IPA network 
analysis was utilized. Network analysis using IPA graphically displays nodes (gene products) and edges 
(biological relationships between the nodes). The colour intensity of the nodes indicates the extent of 
up or down-regulation. IPA identified networks associated with proteins in the datasets of the three cell 
lines. These networks were scored and displayed in order of highest score (table F in appendix). Each 
network was listed with its respective top functions and diseases. To gain an understanding of the 
interaction of these molecules IPA generated networks display the connections between the related 
proteins.  
 
The top scoring molecular networks in the BPH-1 dataset shown in figure 3.10 below. Diseases and 
functions associated with the highest scoring network include: cellular growth and proliferation, gene 
expression (figure 3.10A). This network overlapped with 12 proteins from the BPH-1 dataset and had a 
BPH-1 LNCaP PC3 
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score of 7. Upregulated molecules included CDCA5, KRT18, NCOR2 and PRDX1. Downregulated 
molecules included CALU, CTNNBIP1, ENO1, HNRNPA1, HNRNPK, HSP90AB1, HSPA8, STK4 and 
TACC2. The second scoring molecular network was associated with cell death and survival, cell 
development, cellular growth and proliferation (figure 3.10B). This network overlapped with 13 proteins 
from the BPH-1 dataset and had a score of 6. Upregulated molecules included AGR2, MIF, NUMA1, 
PDLIM7, TPD52 and TPX2. Downregulated molecules included CD44, CDH1, CDKN1B, IL1RN, MCMC 
and PA2G4. The third scoring BPH-1 network was mapped to the following diseases and functions: cell 
death and survival, organismal injury and abnormalities, neurological disease (figure 3.10C). This 
network overlapped with 6 proteins from the BPH-1 dataset and had a score of 5. Downregulated 

























Figure 3.10: Biological network analysis of BPH-1 gene products showing molecular interactions in (A) 
AR- KLK-3 related pathway (B) AR related pathway (C) AR- BCL-2 related pathway. Lines indicate 
relationships and the arrows at the end of these lines show the direction of the interaction. Lines without 
arrowheads show a binding interaction. Dotted lines indicate an indirect interaction. Up-regulated 
molecules are coloured red while down regulated molecules are coloured green. Molecules coloured 
grey do not meet the cut-off threshold while molecules coloured white are added from the Ingenuity 
Knowledge Base.   
  
C 
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3.4 Analysis of the secretome  
Secretome samples were collected from four prostate cell lines following the optimisation of seeding 
density described above in section 2.2.3. The samples, which included three independent biological 
replicates were all prepared using acetone precipitation. Unfortunately, these samples could not be 
analysed by LC-MS/MS in time for the submission of this thesis due to technical difficulties. Construction 
in the building in which the mass spectrometer is housed resulted in the instrument being taken off line 
until such time that the renovations are completed and the instrument serviced. However, secretome 
preliminary secretome samples from the BPH-1 and PC3 cell lines were previously analysed by LC-
MS/MS in order to investigate the proof of concept. It should, however be noted that these only included 
a single biological replicate and the proteins were precipitated by ammonium sulphate. A total of 120 
proteins were identified in BPH-1 and 173 proteins were identified in PC3 secretome. Of these 46 
proteins (table 3.1) were unique to BPH-1 while 99 proteins were unique to PC3. The proteins that were 
differentially expressed in BPH-1 were uploaded on IPA and analysed using the biomarker filter feature 
to identify possible biomarkers for BPH. However, the biomarker search did not yield any novel or 
existing putative biomarkers for BPH.  Several putative PCa biomarkers such as galectin-3, IL-6 and α-
fetoprotein were identified in the BPH-1 secretome which potentially renders them unsuitable as 










Figure 3.11: Comparison of the cell secretome between BPH-1 and PC3 cell line. Each circle in the 
Venn diagram represents a cell line and the relative abundance of secreted protein unique to each cell 
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Table 3.1: Proteins identified in the BPH-1 cell secretome, but not the PC3 secretome. 
Uniprot ID Protein Name Gene Name 
Q9UBP4 Dickkopf-related protein 3 DKK3 REIC 
UNQ258/PRO295 
P00533 Epidermal growth factor receptor EGFR ERBB ERBB1 
HER1 
Q12904 Aminoacyl tRNA synthase complex-interacting 
multifunctional protein 1 
AIMP1 EMAP2 SCYE1 
Q9GZN4 Brain-specific serine protease 4 PRSS22 BSSP4 
PRSS26 SP001LA 
UNQ302/PRO343 
Q8IUL8 Cartilage intermediate layer protein 2 CILP2 
O95084 Serine protease 23 PRSS23 ZSIG13 
UNQ270/PRO307 
Q29960 HLA class I histocompatibility antigen, Cw-16 α chain HLA-C HLAC 
P05155 Plasma protease C1 inhibitor SERPING1 C1IN C1NH 




Q15582 Transforming growth factor-β-induced protein ig-h3 TGFBI BIGH3 
P05543 Thyroxine-binding globulin SERPINA7 TBG 
P61812 Transforming growth factor β-2 TGFB2 
Q14767 Latent-transforming growth factor β-binding protein 2 LTBP2 C14orf141 
LTBP3 
Q96EE4 Coiled-coil domain-containing protein 126 CCDC126 
UNQ786/PRO1605 
Q92563 Testican-2 SPOCK2 KIAA0275 
TICN2 
UNQ269/PRO306 
P25311 Zinc-α-2-glycoprotein AZGP1 ZAG ZNGP1 
Q13751 Laminin subunit β-3 LAMB3 LAMNB1 
Q14508 WAP four-disulfide core domain protein 2 WFDC2 HE4 WAP5 
P00813 Adenosine deaminase ADA ADA1 
Q16557 Pregnancy-specific β-1-glycoprotein 3 PSG3 
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Q6UY14 ADAMTS-like protein 4 ADAMTSL4 TSRC1 
PP1396 
UNQ2803/PRO34012 
P01024 Complement C3 C3 CPAMD1 
Q12805 EGF-containing fibulin-like extracellular matrix protein 1 EFEMP1 FBLN3 FBNL 
P14780 Matrix metalloproteinase-9 MMP9 CLG4B 
P13497 Bone morphogenetic protein 1 BMP1 PCOLC 
Q8NCW5 NAD NAXE AIBP APOA1BP 
YJEFN1 
P15151 Poliovirus receptor PVR PVS 
O60687 Sushi repeat-containing protein SRPX2 SRPX2 SRPUL 
Q13421 Mesothelin MSLN MPF 
Q9Y337 Kallikrein-5 KLK5 SCTE 
UNQ570/PRO1132 
P17936 Insulin-like growth factor-binding protein 3 IGFBP3 IBP3 
P20908 Collagen α-1 COL5A1 
P17931 Galectin-3 LGALS3 MAC2 
A6NKQ9 Choriogonadotropin subunit β-variant 1 CGB1 
Q99523 Sortilin SORT1 
O00300 Tumor necrosis factor receptor superfamily member 
11B 
TNFRSF11B OCIF OPG 
P05231 Interleukin-6 IL6 IFNB2 
Q92876 Kallikrein-6 KLK6 PRSS18 PRSS9 
P36952 Serpin B5 SERPINB5 PI5 
P01008 Antithrombin-III SERPINC1 AT3 
PRO0309 
Q76M96 Coiled-coil domain-containing protein 80 CCDC80 DRO1 URB 
HBE245 
P02765 α-2-HS-glycoprotein AHSG FETUA PRO2743 
Q15828 Cystatin-M CST6 
P02771 α-fetoprotein AFP HPAFP 
Q8WVN6 Secreted and transmembrane protein 1 SECTM1 K12 
P13521 Secretogranin-2 SCG2 CHGC 
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Prostate cancer is the second most prevalent non-cutaneous malignancy affecting men in the world 
(34). The current method for screening and diagnosis of prostate cancer relies on the measurement of 
serum levels of kallikrein 3 (KLK3) in conjunction with the digital rectal exam. However, serum KLK3, 
or prostate specific antigen (PSA) as it is better known, is also elevated by BPH (2). Consequently, a 
major challenge in the treatment and management of this disease is the ability to discriminate between 
prostate cancer and benign tumours such as BPH. Misdiagnosis of prostate cancer entails unnecessary 
treatment for patients which culminates in psychological stress and physical discomfort (2). Although 
PSA has been shown to be ineffective as a true biomarker, it is still used as the primary diagnostic tool 
for the detection of prostate cancer. This is largely due to lack of an alternative and it is therefore crucial 
to find a new biomarker which can distinguish malignant prostate cancer from benign prostatic 
hyperplasia.  
4.1 Secretome optimization  
In this study the proteome and secretomes of four prostate cell lines, representing different conditions, 
were investigated with the aim of identifying novel biomarkers which could distinguish BPH from PCa. 
The PC3 and LNCaP cell lines were used to represent malignant prostate tumours, while the non-
transformed epithelial prostate cell line, BPH-1, was used to represent BPH. The normal prostate 
epithelial cell line, PNT2, was used as a healthy control for all experiments.  
Analysis of conditioned serum free media from different prostate cell lines offers an attractive method 
for biomarker discovery for several reasons. Firstly, serum free culture media is relatively less complex 
when compared to human serum, which is highly complex with dynamic protein concentrations ranging 
up to 12 orders of magnitude. The highly abundant proteins often prevent the ionization and subsequent 
identification of low abundant secretome proteins during MS. Secondly, the biological homogeneity of 
each cell line translates to reproducible results relative to tissue or serum samples. Lastly, prostate cell 
lines are easy to grow and maintain which greatly reduces sample preparation time. The latter property 
of prostate cell lines coupled to the simple complexity of serum free media results in rapid MS profiling 
of the cancer proteomes and secretomes.  
Despite the use of serum free conditioned media offering several advantages for biomarker studies, 
this strategy it is not without its challenges. Intracellular proteins are released into the conditioned media 
at the onset of cell death when the cell membrane ruptures. These intracellular proteins are several 
times more abundant than secreted proteins and therefore can have a masking effect on the secretome 
during MS analysis. Growth conditions of the prostate cell lines must therefore be optimized in order to 
reduce cell death and maximize secreted proteins. LDH and total protein levels in the secretome were 
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therefore measured from three different seeding densities for each cell line (figures 3.1 and 3.2).  A low 
LDH concentration indicates less cell death which correlates to less intracellular proteins in a sample. 
The ratio of LDH/Protein was then calculated to determine the sample with less intracellular proteins 
and more secreted proteins. Therefore, both the LDH/Protein ratio and LDH concentration were 
evaluated and taken into consideration for the determination of the optimal seeding density to increase 
protein coverage during MS analysis. Despite the lowest seeding densities not always having the lowest 
ratio value they were selected for LC-MS/MS analysis due to their relatively low LDH concentration 
(figure 3.3). The selected seeding densities were as follows: BPH-1; 2×106, LNCaP; 11×106, PNT2; 
4×106, PC3; 5×106. In a previous study of the cell secretome by Sardana et al. the optimal seeding 
densities for PC3 and LNCaP were 7.5×106 and 22×106 cells respectively (2). It must be noted the latter 
study used a roller bottle cell culturing method which greatly reduced the amount of cell death and 
therefore allowed for higher seeding densities.  
4.2 Protein purification optimization 
Four different protein precipitation techniques were evaluated for their effectiveness in recovering 
protein from the conditioned serum free medium (figure 3.4). The chloroform-methanol method yielded 
poor results due to difficulty in isolating small amounts of protein from the solvent interphase as well as 
the difficulty of handling the large solvent volumes required by this method. This method was therefore 
excluded from further analyses. When comparing the remaining methods, the acetone based 
precipitation techniques (acetone and acetone-PTA) resulted in up to 20-fold higher protein recoveries 
than the ammonium sulphate precipitation technique. This large disparity in the effectiveness of the 
methods can be attributed to the biochemical modes of precipitation (described in section 3.2). Acetone 
based techniques remove solvation layers around proteins as well as denature the proteins leading to 
greater association of hydrophobic groups and larger protein aggregates which are able to trap smaller 
proteins when they associate. Conversely, the ammonium sulphate method relies solely on the removal 
of solvation around proteins. Therefore, the dual mode of action of acetone precipitation clearly results 
in greater protein recovery from conditioned media. Acetone precipitation also offers a more a more 
attractive method as it minimizes keratin contamination which is an inevitable consequence of sample 
preparation and reduces protein identification. Interestingly, acetone used in combination with PTA 
resulted in a smaller amount of recovered protein relative to the PTA free acetone precipitation method. 
The smaller protein yield is likely due to the protein being difficult to re-suspend in deionized water 
subsequent to precipitation and residual PTA interfering with the BCA protein determination assay. Cell 
secretome studies by Sardana et al. and Kulasingham et al. both employed ammonium sulphate 
precipitation to isolate protein from the conditioned media (2,63) 
4.3 Characterization of the proteome 
The proteome refers to the total ensemble of protein that constitute a cell. Therefore, the comparative 
study of prostate cell line proteomes allowed us to decipher the differences between two disease states. 
The total number of proteins identified per cell line were as follows: 2079 in BPH-1, 2081 in LNCaP, 
1853 in PC3 and 2137 proteins in the PNT2 cell line. Approximately 25% of the identified proteins were 
unique to each cell line. This difference in protein composition among the cell lines highlights the 
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heterogeneity of these cell lines, even though they all originate from the prostate epithelium. Tumour 
heterogeneity arises from multiple non-identical mutations occurring in a given tumour. It may therefore 
be more feasible to identify a panel of biomarkers as opposed to a single biomarker in order to account 
for this heterogeneity. Another factor taken into consideration in this study was that in vitro conditions 
differ considerably from the physiological environment. This greatly impacts on the composition of the 
proteome and some of the proteins identified in this study may not be relevant under in vivo conditions. 
It is therefore imperative to subsequently conduct validation studies of candidate tumour markers.  
  
The positively identified proteins were cross referenced on the Gene Ontology database to determine 
their subcellular localization (figure 3.6). Approximately 49% of annotated proteins were found to be 
intracellular. Unclassified protein accounted for approximately 40% of the total identified proteins. 
Although the percentage of membrane and extracellular proteins identified from the proteome were 
relatively low, these still accounted for (7%) and (11%) of the total number of proteins identified, 
respectively. Extracellular and membrane bound proteins are most likely to be secreted or shed into 
circulation and therefore present attractive targets for biomarker discovery as they can be easily 
obtained from blood serum and subsequently analysed. Candidate biomarkers for BPH were therefore 
identified by comparative analysis of extracellular and membrane bound proteins in all prostate cell 
lines used in this study. Of the 110 proteins that were unique to BPH-1 (table G in the appendix) only 
one protein, mesencephalic astrocyte-derived neurotrophic factor (MANF) was identified as a potential 
biomarker for BPH. The remainder of the proteins unique to BPH-1 have previously been implicated in 
PCa and other cancers, and are being investigated as potential biomarkers for those respective 
diseases. These proteins were disqualified as potential BPH tumour markers as there is a high 
likelihood they will fail to discriminate between the malignant and benign prostate tumours. Proteins 
identified in other cancer types were also disqualified as it is not uncommon for malignant cells, 
regardless of localization or tissue type, to exhibit similar secretome profiles or even share biomarkers.  
MANF is a secreted protein that is produced in response to ER related stress and protects somatic cells 
from inflammatory response damage. In normal mammalian cells the ER triggers the activation of a 
pathway known as unfolded protein response (UPR) in response to the accumulation of misfolded 
proteins. This pathway can also be activated in response to ER stress caused by inflammation, and 
MANF has been shown to be upregulated in patients with inflammatory diseases (154). Inflammation is 
a key factor in the development of BPH and PCa. The prostate is an immunocompetent organ with over 
90% of leucocytes present being CD8+ T lymphocytes (155). The inflammatory response in BPH is 
thought to be immune mediated by these T-cells in response to external stimuli such as a bacterial 
infections, viral infections, chemical irritation and sexually transmitted diseases (156). External stimuli 
trigger an immune response characterized by T-cells releasing cytokines and growth factors which in 
turn cause damage to prostate cells, chronic inflammation and abnormal remodelling of fibromuscular 
tissue. IL-8 is one such cytokine released by T-cells and triggers the expression of FGF-2 which 
stimulates abnormal stromal and epithelial cell growth. Another cytokine implicated in BPH is TGF-β 
which has been shown to be elevated in BPH tissue (155). Further evidence of the connection between 
inflammation and BPH was provided by IPA disease and function analysis of BPH-1 which mapped a 
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T-cell mediated inflammatory response to BPH-1 (discussed in section 4.4.5). Mediators of the 
inflammatory response in the prostate can therefore potentially serve as a source of biomarkers in BPH. 
However, while chronic inflammation in the prostate may be a causative factor for the development of 
BPH it has also implicated in prostate carcinogenesis. In PCa, two inflammatory cytokines have been 
identified that are thought to have a link to prostate carcinogenesis. Macrophage inhibitory cytokine 
(MIC) is one such cytokine that is upregulated in PCa. The levels of MIC in circulation are elevated in 
PCa and it is linked to a poor prognosis in PCa patients. The second cytokine is IL-6 along with its 
receptor IL-6R which are known to be upregulated in PCa. The levels of IL-6 in circulation are elevated 
in both metastatic and hormone refractory PCa and it has already been identified as a promising 
biomarker for PCa. IL-6 is thought to have a contributory role in the initiation and progression of PCa. It 
has also been detected in malignant tissue and high grade PIN (157). Chronic inflammation is also 
thought to lead to the development of proliferative inflammatory atrophy (PIA) (158). PIA is 
characterized by regions of the prostate regenerating at a high frequency in response to tissue damage 
(157). These atrophic lesions often merge with high grade PIN and are therefore considered to be 
precursors of prostate cancer (157). Although inflammation has been implicated in both BHP and PCa, 
there are several delineating factors in the inflammatory response of both diseases that may be able to 
distinguish them. Firstly, local hypoxia induced in the prostate during BPH triggers prostate cells to 
secrete growth factors such as FGF-7, TGF-β, IL-8 and FGF-2 (159). Localized hypoxia in the central 
zone of the prostate is characteristic of BPH and does not commonly occur in PCa. Secondly, 
proinflammatory cytokines such as IL-17 (overexpressed by T-cells in 79% of BPH patients), IL-5 in 
stromal cells and IL-7 in infiltrating T-cells have been reported in BPH tissue (155). Elevated levels of 
these cytokines are unique to BPH while elevated serum IL-6 is unique to PCa. Lastly, the 
overexpression of cyclooxygenase-2 by PIA which is characteristic of PCa (158). Therefore, the role of 
chronic inflammation and its infiltrates in the pathogenesis of the prostate could be further explored to 
develop strategies to detect and treat BPH.    
In this study, approximately 75% of the BPH-1 secretome profile was shared with the secretome profiles 
of either LNCaP, PC3 or PNT2. This indicates that all prostate cells share similar modes of cell signalling 
to mediate intercellular communication. Furthermore, the similarity in the secretome profile greatly 
increases the challenge of finding novel biomarkers to distinguish between the BPH and PCa. To 
circumvent this challenge, we decided to investigate aberrant pathways (described in section 3.3.2) 
associated with BPH as these can offer insights into the molecular mechanisms of disease progression 
and present targets for therapeutic intervention. 
4.4 IPA pathway analysis  
In this study a comparative analysis was used to evaluate the relative differences in pathways between 
two disease states (figure 3.8 and figure 3.9). All fold changes were measured relative to the normal 
prostate cell line, PNT2, which was used as a control.  Fold changes were first determined in Scaffold 
prior to IPA analysis and only fold changes with a p-value of less than 0.05 were included in the 
subsequent IPA analysis. Because proteins do not act in isolation in a biological system network 
analysis was needed to analyse their complex interactions and therefore provide a more holistic image 
Stellenbosch University  https://scholar.sun.ac.za
68 
 
of the physiological environment (160). The major advantage of network analysis is that it can be used 
to integrate different omic technologies. Implementing two or more omic strategies in a biomarker study 
can essentially cross validate candidate biomarkers. Additionally, integration can reveal otherwise latent 
biological interactions that can only be elucidated after data analysis of different biochemical entities 
(161). However, despite the widespread use of network analysis in proteomic studies there is one major 
drawback. Since the human proteome has not yet been fully characterized the network knowledgebase 
(in this study IPA) that is used for the analysis only contains a fraction of the full human proteome 
complement. It is therefore probable that the sample datasets that were uploaded into IPA for Core 
Analysis and the subsequent networks that were generated differ quite considerably from the global 
network at the physiological level (162).   
 
Canonical pathways that showed significant alteration in BPH-1 included the antiproliferative role of 
transducer of ERB2 (TOB) in T cell signalling and pyrimidine ribonucleotide de novo biosynthesis 
pathway (figure 3.8). Diseases and functions that showed significant alteration in BPH included cell 
signalling and vitamin and mineral metabolism (figure 3.9). Each of these pathways is briefly discussed 
below. 
4.4.1 Antiproliferative role of TOB in T cell signalling  
T cells are leucocytes that play a major role in the immune response. An effective T cell response 
involves cytokine secretion and clonal expansion. The regulation of T cells and their maintenance in an 
unresponsive state in the absence of antigens is crucial for correct functioning of the immune system. 
Transducer of ERB2 is a negative regulator of T cell proliferation. It exerts its effect by arresting cell 
cycle progression and inhibiting transcription of interleukin-29. Chronic inflammation in the prostate 
gland is known to contribute to the development of BPH (as discussed in section 4.3). Though IPA could 
not predict the activity state of the antiproliferative role of TOB in T cell signalling it is highly probable it 
is down regulated due to the elevated expression of T cells in the prostate in both BPH and PCa. The 
antiproliferative role of TOB in T cell Signalling together with MANF provide further evidence of the 
association of BPH and inflammation and the prostate inflammatory response should therefore be 
investigated to identify biomarkers. 
4.4.2 Pyrimidine ribonucleotide de novo biosynthesis, cell signalling and vitamin and 
mineral metabolism 
The pyrimidine ribonucleotide biosynthesis pathway is an energy consuming pathway that synthesizes 
precursors for DNA and RNA in the cell. Pyrimidines are six carbon cyclic compounds with a nitrogen 
atom attached at the 1 and 3 position. Conjugation of a ribose sugar at carbon position 1 on the 
nitrogenous base results in the formation of a ribonucleoside. Subsequent attachment of one or more 
phosphate groups to the number 5 position of the ribose sugar forms a pyrimidine ribonucleotide. De 
novo pyrimidine synthesis occurs in the cytoplasm and results in the formation of CTP and UTP. Both 
nucleotides serve as energy sources with CTP being involved in lipid metabolism while UTP activates 
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glucose and galactose (163). BPH-1 showed greater association with this pathway relative to the PCa 
cell lines. PCa is a slow developing disease relative to other cancer types that mostly exhibits symptoms 
in its advanced stages10. In addition to this malignant prostate cells are localized in the peripheral zone 
of the prostate and are involved in a host of interactions with neighbouring cells. Conversely, BPH cells 
are localized in the central zone of the prostate where they replicate indefinitely at a relatively faster 
rate (164). As a result of the more homogenous cell population and increased cell proliferation BPH 
cells may require more energy to sustain cell replication as well as nucleic acids which provide the 
framework for this replication. Network analysis of BPH-1 (figure 3.10) provided further evidence of this 
hyperproliferation through the following network enriched functions: cell death and survival, cell 
development, cellular growth and proliferation. The AR was a central node in all networks generated 
from BPH-1. Dysregulation of the AR is a feature mostly associated with PCa but as both diseases are 
androgen dependent it is plausible that this also occurs in BPH. This dysregulation of the AR in 
combination with aberrant cell signalling, and vitamin and mineral metabolism (reported in the disease 
and function analysis, section 3.3.4) may account for the increased rate of cell proliferation in BPH. The 
HSPA5 gene was mapped to both cell signalling and vitamin and mineral metabolism, and encodes 
Heat shock 70-kDa protein 5 (HSPA5). HSPA5 is involved in calcium homeostasis and acts as a signal 
receptor localized in the plasma membrane. Intracellular calcium (Ca2+) is involved in the regulation of 
cell processes such as gene expression and cell proliferation. The Ca2+ signalling cascade is 
considerably altered during tumorigenesis to facilitate evasion of apoptosis and increased cell 
proliferation (152,153) . 
4.5 Preliminary secretome analysis  
The secretome comprises of proteins that are shed or secreted by cell, tissue or organism. The 
secretome of prostate cell lines provides a rich source of biomarkers as these proteins are often 
implicated in signalling processes promoting tumour progression such as proliferation, metastasis, 
angiogenesis and evasion of apoptosis. The secretome samples that were prepared as described in 
section 2.2.3 could not be analysed by LC-MS/MS due to technical difficulties beyond our control. 
Construction in the building in which the mass spectrometer is housed resulted in the instrument being 
taken off line until such time that the renovations were completed and the instrument serviced. 
Preliminary comparative analysis of the PC3 and BPH-1 secretome profiles did however identify 46 
proteins unique to the BPH-1 cell line. These proteins were uploaded in IPA and analysed by the 
biomarker feature to identify potential biomarkers. A literature search was also conducted in support of 
the IPA biomarker filter analysis. The search did not yield any potential biomarkers as most of the 
proteins were either already identified in similar biomarker studies as potential PCa biomarkers or were 
implicated in PCa development and progression and would therefore not be suitable to distinguish BPH 
from PCa. The lack of any viable biomarkers from this preliminary investigation can be attributed to the 
ammonium sulphate precipitation method that was used for protein purification. As reported in section 
3.2 there was a significant fold increase in the amount of protein recovered by acetone precipitation 
relative to ammonium sulphate. Therefore, the poorer protein purification method that was used in this 
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preliminary study may have drastically reduced the amount of secreted proteins that could be recovered 
and subsequently identified by MS. This preliminary secretome study did however provide proof of 
concept. Furthermore, the identification of putative PCa biomarkers such as galectin-3, α-fetoprotein 
and IL-6 in the secretome of BPH-1 cells suggests that many of these proteins would not be suitable 
biomarkers for PCa as, like PSA, they may not distinguish between PCa and BPH. This therefore 
illustrates the use of testing secretome samples from representative cell lines in combination with 
secretomes obtained from serum or urine.  
4.6 Conclusion 
After optimization of prostate cell line growth conditions, the lowest seeding densities were selected for 
all samples due to the lower amount of intracellular proteins in these samples as abundant intracellular 
proteins have a masking effect during MS analysis. Optimization of protein purification identified 
acetone precipitation as the best method for isolating proteins from serum free media due to its dual 
mode of action that involved denaturing and removing solvation layers from proteins. Although 
secretome samples were prepared for analysis by LC-MS/MS, these samples could not be analysed 
due to technical difficulties and will be will be completed in future.  
The proteome of four prostate cell lines were instead analysed by LC-MS/MS to identify potential 
biomarkers which can be used to distinguish BPH from PCa. The secreted protein MANF was identified 
as candidate tumour marker in this regard. MANF is a secreted protein associated with inflammation 
and this further pointed towards the association of BPH with a chronic inflammatory response. It is, 
however, unlikely that a single prognostic biomarker can be used across different populations due to 
tumour heterogeneity. The candidate biomarker identified in this study could therefore potentially be 
used in tandem with current or emerging biomarkers of PCa and BPH. Prior to implementation as a 
prognostic tool the protein would have to undergo stringent validation trials in animal models and patient 
serum.  
In addition to analysis of differentially expressed proteins in the proteome of the prostate cell lines, we 
investigated pathways that were affected in BPH relative to PCa. These included Pyrimidine 
ribonucleotides de novo biosynthesis and the antiproliferative role of TOB in T cell signalling. 
Interestingly both the latter mentioned pathway and candidate biomarker are involved in the 
inflammatory response. Further investigation of the role of this pathway in BPH as well as an 
investigation of pathways involved in the immune mediated inflammatory response in prostate cells 
could yield targets for pharmacological intervention. Pyrimidine ribonucleotide de novo biosynthesis and 
vitamin and mineral metabolism pointed to an increased rate of cell proliferation in BPH relative to PCa 
and may account for the greater prostate mass measured in BPH patients relative to PCa. Targeting 
nucleic acid synthesis via the pyrimidine ribonucleotide de novo biosynthesis in BPH cells may deprive 
tumour cells of a valuable energy source and reduce the rate of cell proliferation. Abnormal vitamin and 
mineral metabolism is linked to dysregulated Ca2+ signalling. Since Ca2+ signalling is involved in cell 
survival and proliferation, inhibiting the mitochondrial uptake may provide an effective remedy in BPH 
treatment.    
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Preliminary analysis of the secretome did not identify any candidate biomarkers but provided proof of 
concept. Differential analysis of the secretome may provide a more promising source of biomarkers 
relative to differential analysis of the cell proteome. This is due to optimization of cell culture growth 
conditions which effectively concentrates secreted proteins and allows for greater secreted protein 
coverage by MS. 
4.7 Future studies  
The comparative analysis of the proteome identified MANF as candidate biomarker for BPH. The clinical 
utility of this protein as a diagnostic tool to distinguish the benign from malignant prostate cancer is at 
this stage unknown. Future studies must therefore focus on validating the presence and effectiveness 
of MANF in patient serum by conducting immunoassays. MS quantification methods could also be used 
to measure the amount of serum MANF and correlate this to disease stage. The role of MANF in BPH 
could further be investigated by gene knockout experiments. Pathways that were found to be altered in 
the BPH disease state by IPA can be further analysed to yield biomarkers by analysis of their metabolic 
profile. This would entail integration of proteomics and metabolomics. Interpretation of proteomic data 
through in silico network analysis can identify pathways involved in pathogenesis. These pathways can 
then be further investigated by metabolomics to analyse the interaction of gene and protein downstream 
products. Furthermore, BPH showed an association with chronic inflammation in the prostate and this 
can also be further investigated to understand the role this inflammatory response and identify possible 
biomarkers for BPH. 
Due to a technical fault the secretome of all prostate cell lines could not be analysed. Future 
investigations must augment the analysis of the cell secretome by the addition of several experimental 
conditions. Firstly, additional prostate cancer cell lines, such as DU145, 22Rv1, VCaP and PPC-1, can 
be added to the study in order to further enrich the secretome profile of PCa. Secondly, as this study 
was conducted in the absence of androgens the effect of androgens must be investigated to understand 
their influence on protein expression. Lastly, prostate cells may be co-cultured with stromal cells and 
CD8+ cells to in a 3D-culture model to better match physiological conditions and gain insights on the 
immune mediated inflammatory response in disease aetiology. 
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Table G: Extracellular and membrane proteins identified in the BPH-1 cell proteome, but not the other 
prostate cell lines. 
Uniprot ID Protein Name Gene Name 
Q7L7L0 Histone H2A type 3 HIST3H2A 
Q16777 Histone H2A type 2-C  HIST2H2AC H2AFQ 
Q9BTM1 Histone H2A.J  H2AFJ 
Q8IUE6 Histone H2A type 2-B HIST2H2AB 
P16104 Histone H2AX  H2AFX H2AX 
Q96QV6 Histone H2A type 1-A  HIST1H2AA H2AFR 
P10412 Histone H1.4  HIST1H1E H1F4 
Q01546 Keratin, type II cytoskeletal 2 oral  KRT76 KRT2B KRT2P 
P37802 Transgelin-2  TAGLN2 KIAA0120 
CDABP0035 
P51858 Hepatoma-derived growth factor  HDGF HMG1L2 
O95171 Sciellin SCEL 
P68036 Ubiquitin-conjugating enzyme E2 L3  UBE2L3 UBCE7 
UBCH7 
P48637 Glutathione synthetase  GSS 
P53999 Activated RNA polymerase II transcriptional coactivator 
p15  
SUB1 PC4 RPO2TC1 
O75347 Tubulin-specific chaperone A  TBCA 
P07108 Acyl-CoA-binding protein  DBI 
P04179 Superoxide dismutase, mitochondrial  SOD2 
P55145 Mesencephalic astrocyte-derived neurotrophic factor  MANF ARMET ARP 
Q15843 NEDD8  NEDD8 
Q9UBG3 Cornulin  CRNN C1orf10 DRC1 
PDRC1 SEP53 
P13646 Keratin, type I cytoskeletal 13  KRT13 
P06702 Protein S100-A9  S100A9 CAGB CFAG 
MRP14 
P50502 Hsc70-interacting protein  ST13 AAG2 FAM10A1 
HIP SNC6 
P63208 S-phase kinase-associated protein 1  SKP1 EMC19 OCP2 
SKP1A TCEB1L 
Q9H3K6 BolA-like protein 2 BOLA2 BOLA2A My016; 
BOLA2B 
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P61088 Ubiquitin-conjugating enzyme E2 N  UBE2N BLU 
Q5JXB2 Putative ubiquitin-conjugating enzyme E2 N-like  UBE2NL 
P31151 Protein S100-A7  S100A7 PSOR1 
S100A7C 
P19957 Elafin  PI3 WAP3 WFDC14 
Q07065 Cytoskeleton-associated protein 4  CKAP4 
P12277 Creatine kinase B-type  CKB CKBB 
A6NHG4 D-dopachrome decarboxylase-like protein  DDTL 
Q92817 Envoplakin  EVPL 
H7C469 Uncharacterized protein   
Q04760 Lactoylglutathione lyase  GLO1 
Q96FQ6 Protein S100-A16  S100A16 S100F AAG13 
O75531 Barrier-to-autointegration factor  BANF1 BAF BCRG1 
O14896 Interferon regulatory factor 6  IRF6 
P08779 Keratin, type I cytoskeletal 16  KRT16 KRT16A 
P01040 Cystatin-A  CSTA STF1 STFA 
O15020 Spectrin β-chain, non-erythrocytic 2  SPTBN2 KIAA0302 
SCA5 
P29508 Serpin B3  SERPINB3 SCCA 
SCCA1 
O95785 Protein Wiz  WIZ ZNF803 
Q96NY8 Nectin-4  NECTIN4 LNIR PRR4 
PVRL4 
Q9HCY8 Protein S100-A14  S100A14 S100A15 
O00115 Deoxyribonuclease-2-α  DNASE2 DNASE2A 
DNL2 
O76070 Gamma-synuclein  SNCG BCSG1 PERSYN 
PRSN 
P32926 Desmoglein-3  DSG3 CDHF6 
Q9NZH8 Interleukin-36 gamma  IL36G IL1E IL1F9 IL1H1 
IL1RP2 
UNQ2456/PRO5737 
P06744 Glucose-6-phosphate isomerase  GPI 
P46940 Ras GTPase-activating-like protein IQGAP1  IQGAP1 KIAA0051 
P47929 Galectin-7  LGALS7 PIG1; 
LGALS7B 
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Q9UMD9 Collagen α-1 COL17A1 BP180 
BPAG2 
Q9H0E2 Toll-interacting protein TOLLIP 
P12268 Inosine-5'-monophosphate dehydrogenase 2  IMPDH2 IMPD2 
P46531 Neurogenic locus notch homolog protein 1  NOTCH1 TAN1 
P62826 GTP-binding nuclear protein Ran  RAN ARA24 OK/SW-
cl.81 
P01772 Immunoglobulin heavy variable 3-33  IGHV3-33 
P16152 Carbonyl reductase [NADPH] 1  CBR1 CBR CRN 
SDR21C1 
P35232 Prohibitin PHB 
P62269 40S ribosomal protein S18  RPS18 D6S218E 
P01767 Immunoglobulin heavy variable 3-53  IGHV3-53 
Q86Y46 Keratin, type II cytoskeletal 73  KRT73 K6IRS3 KB36 
KRT6IRS3 
P78310 Coxsackievirus and adenovirus receptor  CXADR CAR 
Q9Y265 RuvB-like 1  RUVBL1 INO80H 
NMP238 TIP49 TIP49A 
Q96CF2 Charged multivesicular body protein 4c  CHMP4C SHAX3 
P11279 Lysosome-associated membrane glycoprotein 1  LAMP1 
P36952 Serpin B5  SERPINB5 PI5 
Q9BW30 Tubulin polymerization-promoting protein family 
member 3  
TPPP3 CGI-38 
P50452 Serpin B8  SERPINB8 PI8 
Q9H190 Syntenin-2  SDCBP2 SITAC18 
P19012 Keratin, type I cytoskeletal 15  KRT15 KRTB 
Q6ZSZ5 Rho guanine nucleotide exchange factor 18  ARHGEF18 KIAA0521 
P22087 rRNA 2'-O-methyltransferase fibrillarin  FBL FIB1 FLRN 
P05198 Eukaryotic translation initiation factor 2 subunit 1  EIF2S1 EIF2A 
P53990 IST1 homolog  IST1 KIAA0174 
Q5VT79 Annexin A8-like protein 1 ANXA8L1 ANXA8L2 
P00918 Carbonic anhydrase 2  CA2 
Q9NZT1 Calmodulin-like protein 5  CALML5 CLSP 
P12004 Proliferating cell nuclear antigen  PCNA 
O43175 D-3-phosphoglycerate dehydrogenase  PHGDH PGDH3 
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Q9UNN8 Endothelial protein C receptor  PROCR EPCR 
P12830 Cadherin-1  CDH1 CDHE UVO 
P39023 60S ribosomal protein L3  RPL3 OK/SW-cl.32 
P63244 Receptor of activated protein C kinase 1  RACK1 GNB2L1 HLC7 
PIG21 
Q9UN37 Vacuolar protein sorting-associated protein 4A  VPS4A VPS4 
P62280 40S ribosomal protein S11 RPS11 
P20933 N(4)-( β-N-acetylglucosaminyl)-L-asparaginase AGA 
Q5JSG7 Proprotein convertase subtilisin/kexin type 5  PCSK5 
P16333 Cytoplasmic protein NCK1  NCK1 NCK 
Q8TD16 Protein bicaudal D homolog 2  BICD2 KIAA0699 
Q9NP74 Palmdelphin  PALMD C1orf11 PALML 
E7EPK1 Septin-7 SEPT7 
O94906 Pre-mRNA-processing factor 6  PRPF6 C20orf14 
Q9Y4H2 Insulin receptor substrate 2  IRS2 
P48230 Transmembrane 4 L6 family member 4  TM4SF4 ILTMP 
Q9NVP1 ATP-dependent RNA helicase DDX18  DDX18 cPERP-D 
Q9C0B5 Palmitoyltransferase ZDHHC5  ZDHHC5 KIAA1748 
ZNF375 
Q8TAE6 Protein phosphatase 1 regulatory subunit 14C  PPP1R14C KEPI 
E9PCW0 Prohibitin  PHB 
Q53RT3 Retroviral-like aspartic protease 1  ASPRV1 SASP 
Q9Y6M5 Zinc transporter 1  SLC30A1 ZNT1 
P62760 Visinin-like protein 1  VSNL1 VISL1 
P07949 Proto-oncogene tyrosine-protein kinase receptor Ret  RET CDHF12 CDHR16 
PTC RET51 
P01715 Immunoglobulin lambda variable 3-1  IGLV3-1 
O43639 Cytoplasmic protein NCK2  NCK2 GRB4 
Q9P2E7 Protocadherin-10 PCDH10 KIAA1400 
Q6NZY7 Cdc42 effector protein 5  CDC42EP5 BORG3 
CEP5 
Q9NX40 OCIA domain-containing protein 1  OCIAD1 OCIA 
P59551 Taste receptor type 2 member 60  TAS2R60 
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